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Abstract 
Immunization via the use of whole pathogen (or its biological component) has been one of 
the most successful public health interventions. Historically, Edward Jenner pioneered the 
modern vaccination in the late 17th century and since; vaccine research has been evolving 
rapidly. The practice of conventional vaccination, with attenuated or killed pathogen, was 
accepted worldwide and with this strategy, protections against many diseases were 
established. Nevertheless, not all diseases can be prevented via the conventional 
vaccination approach. For example, there is no vaccine against group A streptococcus 
(GAS), hookworm or schistosome infection, although recent statistics shows that these 
diseases affect almost a billion people worldwide (i.e. high demand for vaccines). The 
conventional vaccination via the use of weakened or killed GAS pathogen could result in 
the development of fatal autoimmune diseases (i.e. rheumatic fever and rheumatic heart 
disease), while vaccination using whole hookworm or schistosome parasite failed to 
develop protection in human, despite these vaccines were successful in animal (murine 
and/or canine) models. Therefore, synthetic vaccination approach via the use of minimal 
pathologic component (subunit peptide) necessary to stimulate immune response has the 
potential to address the drawbacks of using conventional vaccination approach. However, 
as peptides are poor immunogens on their own, the approach necessitates the use of 
adjuvants (immunostimulant) or carrier molecules to boost the vaccines’ immunogenicity. 
In this PhD research project, novel carrier systems/delivery platforms were utilized for the 
development of synthetic (subunit) vaccines against three pathogens: Streptococcus 
pyogenes (GAS), Necator americanus (hookworm) and Schistosoma mansoni 
(schistosome). Two types of acrylate polymers, linear- and dendritic-poly(t-butyl)acrylate 
(PtBA), were used for the GAS vaccine development project while the lipid core peptide 
(LCP) systems were used for the development of self-adjuvanting vaccines against 
hookworm and schistosome infections. This research work mainly involved the design of 
peptide epitope, the synthesis of the subunit peptide and the delivery platforms, the 
conjugation peptides to the delivery platforms and immunological evaluation of the vaccine 
candidates in (inbred) mice model.  
In summary: 
• The synthetic pathway to produce self-assembled polymer-peptide hybrid vaccines via 
copper catalysed azide-alkyne cycloaddition (CuAAC) reaction was established for the 
development of vaccine candidates against GAS. The candidates were able to form 
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distinct nanoparticles with sizes of 500 nm and 20 nm, for the linear- and dendritic-
PtBA, respectively. The conjugates were able to stimulate IgG secretion against J14 
peptide after a single-dose immunization, without the use of additional adjuvant. 
• Vaccines that are able to stimulate the humoral response (production of neutralizing 
antibodies) are vital for the development of therapeutics against hookworm infection. 
Alternative approach in designing the minimal B-cell peptide epitopes against 
hookworm aspartic protease (APR-1) was established using bioinformatics tools (i.e. 
computational methods). The epitopes were conjugated to two LCP carriers via 
stepwise solid peptide synthesis (SPPS) and CuAAC reactions. The vaccine 
candidates were able to self-assemble into nanoparticles and their potency in eliciting 
IgG antibodies were established. 
• Prior research using LCP vaccine against schistosome parasite was able to produce 
neutralizing IgG antibodies against the parasite’s cathepsin D protein. Unfortunately, 
inconsistencies in the antibody production were observed between mice. Based on the 
preliminary results, novel vaccines were designed to include a T helper epitope and 
synthesized via SPPS. Additionally, a new B cell epitope was designed using 
bioinformatics tools and conjugated to the LCP system bearing a T helper epitope. The 
improved and new vaccine candidates efficiently elicited high antibody titres, 
comparable to the strong but toxic Freund’s adjuvant. 
The poor immunogenicity of peptide-based vaccines was overcome with the application of 
the self-adjuvanting PtBA and LCP carrier systems. The subunit peptides conjugated to 
the carriers have been shown to be able to produce strong antibody response without the 
use of additional toxic adjuvant. These findings suggested that the novel carrier systems 
have great potentials as self-adjuvanting vaccine carriers for the development of subunit 
peptide-based vaccines. 
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1.1 Vaccination: Historical Perspectives 
It is widely known that vaccination, or immunization, has been one of the most successful 
public health interventions in the prevention and management of diseases. A person who 
is exposed to a pathogen, whether symptoms are present or not, will naturally developed 
immunity against the disease. This process is categorised as naturally acquired immunity. 
However, primary exposure to a lethal pathogen (e.g. smallpox) could result in death. 
Records on the first method to artificially acquired protective immunity against diseases 
(via variolation/inoculation) were dated back to the 10th century in China. Using this 
approach, healthy individuals were subjected to the weakened states of the pathogen, i.e. 
by injecting contaminated materials (e.g. liquid from blisters) or rubbing their skin to the 
sick patient’s. This method was proven to be beneficial; however, it comes with a greater 
risk of mounting severe side effects, including the development of disease against which 
the patient was ‘treated’. It was not until the late 17th century that the term vaccination was 
commonly used. Edward Jenner developed alternative approach to the common practice 
at that time. He developed smallpox vaccine by inoculating materials from a milkmaid’s 
blister, caused by cowpox infection. The inoculation resulted in the protection against the 
deadly smallpox [1]. Since then, many milestones in vaccine research were achieved, 
including; the rabies vaccine by Louis Pasteur in the 1880s via the ‘attenuated’ pathogen 
approach; serum therapy and antitoxin by Shibasaburo Kitasato and Emil von Behring in 
the 1890s; and others. These achievements were also contributed by the improvements in 
the discoveries and innovations in bacteriology and virology and thereafter, resulted in the 
development of many safe and cost-effective vaccines as we see today. 
 
1.2 Traditional Vaccination 
The use of a whole pathogen in a vaccine development is also known as conventional or 
traditional vaccination. The approach utilizes live attenuated/killed pathogens or 
inactivated bacterial toxins to initiate an immune response [1]. The approach enables 
elicitation of a protective immunity, usually without the development of major side effects. 
Since its first introduction by Louis Pastuer, traditional vaccination approach became 
increasingly common throughout the globe and has had successes in providing the 
necessary long-lasting immunity (protection) against various diseases such as rabies  
[2, 3], tuberculosis [4], and polio [5]; to name a few. Despite these successes, traditional 
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vaccination is occasionally, hampered with various safety issues and concerns including 
the capacity of an attenuated pathogen to replicate and causing infection, especially in 
immunocompromised individuals, and the administration of the unnecessary pathogenic 
components that could cause mild-to-severe side effects such as the development of 
allergic and autoimmune response [6]. Scientists therefore are looking into alternative 
means of developing safe and well-defined vaccines. Fortunately, the advancement in 
molecular biology has widened the scope for vaccine development due to the discovery of 
minimal microbial components that are able to stimulate desired immune responses (e.g. 
peptides) as vaccines. 
 
1.3 Peptide-based subunit vaccine 
A minimal pathogenic component, or subunit, can be utilized for the development of safer 
vaccines. Subunit vaccines are designed to possess minimal pathogenic component (e.g. 
peptides or polysaccharides) that are necessary to induce the immune response  
(Figure 1) [7]. As these vaccines can be made via chemical or biosynthesis pathways, the 
subunit approach resulted in the development of not infectious; chemically and physically 
more stable, and, usually easier and cheaper to produce in a highly characterized state 
(batch-to-batch consistency) compared to the classical vaccine development approach  
[6, 8]. The construction of the “well-defined” vaccines thus resulted in improved overall 
vaccine safety profile. Additionally, the subunit component can be further modified to 
include other components such as targeting/unnatural modules [9]. Furthermore, the use 
of only minimal pathogenic components greatly reduces risk of autoimmune and allergic 
responses. However, the development of subunit vaccines is often associated with poor 
immunogenicity. This is because as the pathogenic component used is reduced to a 
minimum, the potency of the subunit component to stimulate the immune response is 
much weaker (loss of ‘danger’ signal). Moreover, subunit vaccine approach usually 
requires multiple administrations (boosters) to achieve the similar, prolonged protective 
effect, compared to the traditional vaccines [10-12]. The poor immunogenicity necessitates 
the incorporation of potent immunostimulatory elements (adjuvant or carrier) to boost the 
efficacy of subunit vaccine. 
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Figure 1. Evolution of vaccination; from the traditional vaccines (i.e. whole pathogen) to 
protein-based vaccines and the subunit peptide-based vaccines. 
 
1.4 Principle of vaccinations  
Vaccines work by delivering foreign materials from the pathogen (i.e. antigen) to patients 
by stimulating appropriate humoral (antibodies-mediated) or cellular (cell-mediated) 
immunity (Figure 2). The humoral response primarily plays an important role as the host’s 
sentinel against extracellular organisms, while the cellular response is required to fight 
cancerous cells or intracellular infections. Synthetic vaccines can be designed to trigger 
these ‘acquired’ immunity by delivering specific antigen to the host. 
Antigens can be sub-categorised into two entities; immunogens which are able to generate 
immunological response against them, or, non-immunogens which are able to react with 
antibodies, B cell, or primed T cells, irrespective of their ability to generate immune 
responses. For the purpose of antibody production, the antigens used in vaccines contain 
a B cell and/or helper T cell (Th) epitope that could be recognized by specific receptors on 
antigen presenting cells (APCs) and T cells, respectively. A B cell epitope is required as a 
template for antibody specificity while a Th cell epitope are required as a co-stimulant that 
leads to B cell activation (antibody secretion) and transformation of matured B cell into 
memory B cells. Additionally, the development of antibodies can proceed via two 
mechanisms: a T cell dependent, and a T cell independent (Figure 3). Both mechanisms 
require the presence of a B cell epitope, however, the presence of a Th epitope in the T 
cell independent mechanism is not required. 
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1.4.1 Antigen to antibody production 
Helper T cell dependent pathway (Figure 3A): The process that triggers antibody 
production starts with the recognition of an exogenous antigen (consisting B and Th cell 
epitopes) by receptor on the B cell (thus termed B cell receptor, BCR). Upon binding to the 
BCR, the antigen is transported into the cell via phagocytosis or/and pinocytosis within a 
double membrane endosome. Then, the antigen is processed by partially degraded into 
smaller pieces. The degraded fragments are allowed to bind to the major histocompatibility 
complexes (MHC) class II. Subsequently, the antigen-MHC is transported to the cell 
surface for antigen presentation to the Th cell. Recognition of the antigen-MHC complex 
by the Th cells therefore resulted in the release of co-stimulant that activates B cells into 
releasing antibodies into the blood circulation. 
Helper T cell independent pathway (Figure 3B): In contrast to the dependent mechanism, 
a certain linear polyantigen (e.g. polysaccharides, D-amino acids polymer) that is not 
readily degraded in the body could directly stimulate B cells into producing antibodies. 
With appropriate spacing between the highly repeating antigenic determinants, this long 
polymer could bind multiple BCRs thus leading to BCRs clustering. The clustering 
activates signalling pathways that stimulate the production of antibodies [13]. 
Nevertheless, the independent pathway often resulted to predominantly lower antibody 
response with relatively poor memory B cell maturation [14]. 
 
1.4.1.2 Importance of bioactive conformation in vaccine development 
Proteins are built from specific sequences of amino acids linked via the peptide/amide 
bonds. The restricted flexibility of these bonds, along with intramolecular forces between 
the neighbouring peptide chains (i.e. hydrogen and disulphide bonds, and interactions 
based on van der Waals forces) forms specific topographic (three dimensional) structures. 
As a result, epitopes, made up from specific sequence of amino acids, forms specific 
surface structures (i.e. conformation) that are important for the B cells receptor recognition. 
Much like the lock-and-key theory, the epitope and resultant antibodies complement each 
other. Thus, the inability of a peptide in a subunit peptide-based vaccine to form its native 
conformation can therefore lead to failure in the development of antibodies that are able to 
bind to its target (e.g. parent protein). However, unlike the B cell epitope, the Th epitope is 
independent of its conformation. Rather, antigen processing by APCs is required to 
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produce peptide of a define length (bound to the MHC complexes) for the Th cell 
stimulation [15]. 
 
Figure 2. Schematic representation of immune processes. B-cells and helper T-cells 
lymphocytes are the primary cells that mediate the immunological cascades for the 
induction of a cellular or/and humoral response. Adapted from Azmi et. al.[16] 
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Figure 3. Activation of B-cells via (A) T-cell dependent and (B) T-cell independent 
pathways. In a T-cell dependent pathway, priming of helper T cell and the construction of 
the antigen-major histocompatibility complex class II are the key role in the activation of 
naïve B-cell into mature cells (i.e. plasma and memory B cells) and thus secretion of 
antibodies. However, the T-cell independent is activated via B cell receptor clustering that 
resulted to primarily plasma cells, for antibodies production. 
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1.4.1.3 Stabilizing Peptide Conformation 
It is known that antibodies produced via the administration of subunit peptide-based 
vaccines are conformation-dependent [15]. As such, utilizing short B cell epitopes (with an 
average length of 15 amino acids [17]) for vaccine development will scarcely resulted in 
the stimulation of the desired protective antibody (due to different epitope conformation to 
the parent’s). Therefore, the possibilities of using external methods to promote the short 
peptide to embrace their native conformation are highly desirable. As an example, the 
development of vaccine based on the major virulent factor of group A streptococcus 
(GAS), the M protein, using minimal peptide epitope (J14i, 14 amino acids-long peptide) 
failed to elicit specific antibodies against the parent sequence from M protein (p145, 20 
amino acids); despite antibodies binding to the J14i peptide was observed [18]. However, 
when its derivative, J14 (J14i flanked with additional peptides at both N- and C-termini of 
J14i) was administered as a vaccine, antibody binding against p145 was observed. This is 
because under physiological conditions, the M protein (and its p145 derivatives) folds into 
a single stable conformation (a coiled-coil helix [19]). The additional flanking sequence 
used in J14 was able to promote the formation of a more stable J14i epitope, bearing 
conformational similarities to the native M protein. Consequently, the J14 vaccine was able 
to stimulate the production of antibodies that were able to recognize the parent, coiled-coil 
motif, and thus conferred mice protection in a bacterial challenge experiment [18]. The 
approach of using additional sequence based on foreign or parent peptide is also a widely 
used method to promote, as well as stabilize, peptides’ native conformation [20-23]. 
Besides, stabilization of peptide epitopes secondary structure (helices or sheet) can be 
achieved via chemical means. In an α-helix structure, the 3.6 residues per turn is its 
primordial feature, while a typical β pleated sheet consists of two or more adjacent peptide 
chains that are connected via interstrand hydrogen bonds (Figure 4). The turns place 
specific amino acids side chains to be on the same surface to one another; i, i+4, i+8, and 
i+11 amino acids, while the beta sheet structure allows interstrand amino acid side chains, 
to be in close proximity. This characteristic enables side chain-to-side chain cross-linking 
or head-to-tail cyclization strategy that increases the rigidity of the secondary structures. 
As such, peptides with more stable structures (increase antigenicity?) can be constructed 
and utilized for the development of peptide-based vaccines. For example, Walensky and 
co-workers reported that an enhanced HIV-1 4E10 peptide antigen was constructed via 
side chain-to-side chain stapling. The monoclonal antibody against the 4E10 epitope was 
60-times more potent at binding the stapled peptide than its regular counterparts [24]. 
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The two examples highlighted the importance of bioactive conformation in the 
development of peptide-based vaccines. The possibilities of utilizing peptide flanking- and 
chemical modification-strategies as a tool for the development of peptides with enhanced 
secondary structure could serve as a useful approach in designing a ‘just right’ peptide 
structure that is able to elicit antibody response against its targets. 
 
 
Figure 4. Superimposed cartoon and stick representations of peptide secondary 
structures; (A) α-helix, and (B) anti-parallel beta sheet. Also highlighted in green are the 
amino acid side chains; illustrating their close proximities to enable further modification 
(e.g. side chain locking). 
 
1.4.2 Immunostimulant (Adjuvants/Carriers) 
There are limited numbers of adjuvants that have been licenced for human use [25]. The 
major problems associated with the use of these stimulatory components for vaccines 
development are linked to the adjuvants’ acute toxicity and potential delayed 
reactogenicity [26]. As an example, complete Freund's adjuvant (CFA) is a very potent 
adjuvant, composed of dead mycobacteria (commonly Mycobacterium tuberculosis), 
(A)
(B)
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emulsified in mineral oil [27, 28]. The presence of the bacterial component therein resulted 
in a relatively toxic water-in-oil vaccine formulation that is unfit for human use. Therefore, 
the absent of external microbial-based adjuvant or carrier system is very favourable. 
Several strategies have been examined to deliver peptide epitopes as components of self-
adjuvanting vaccines [29-31]. One of such strategies is to form nano-sized particles. Some 
of the advantages for the development of nano-sized particles are; first, the peptide 
immunogens incorporated into the nanoparticles are presented to the immune system 
more effectively, second, the nanoparticles are more stable against enzymatic 
degradation, and third, the nanovaccines often can be deliver without external adjuvant. 
The nanotechnological approach to produce subunit vaccines is considered to be one of 
the most advantageous [32-36]. 
 
1.4.2.1 Lipid Core Peptide 
Lipid cope peptide (LCP) is a self-adjuvanting vaccine consisting three components, a lipid 
core, carrier/branching moiety and the epitope or antigenic components, all in one entity 
(Figure 5) [37]. This lipid core of the LCP system was designed based on lipopeptide 
component from Escherichia coli’s potent immune-system activator called Pam3Cys [37]. 
The Pam3Cys lipopeptides derivatives can be found in many Gram-positive and Gram-
negative bacteria. For example, in Brucella abortus bacteria, Pam3-modified cysteine was 
shown to be involved in bacterial defence mechanism by down regulating host’s immune 
system [38]. However, when Pam3Cys was used as adjuvant, it was able to stimulate 
immune response against co-delivered antigen, and did not result in the immune system 
down regulation [37, 39, 40]. Though the lipid core component of the LCP mimics the 
lipophilic part of Pam3Cys, the use of LCP as adjuvant is more advantageous as the LCP 
can easily be synthesized following Boc or Fmoc solid phase peptide synthesis (SPPS) 
protocols [41]. Moreover, the structure-activity relationships of the LCP were previously 
optimized by Toth and co-workers [10]. It was reported that the length of the lipid 
component of LCP had strong influence on the immunostimulating properties of the 
adjuvant [10]. In addition to the lipid core, the multiple lysine branching component of the 
LCP (polylysine branching) further helped to overcome the disadvantage of the use of 
subunit peptide-based vaccines by providing multiple peptide conjugative sites, connecting 
the multiple antigens to the lipid core [37, 41]. As a result, LCP vaccines were able to elicit 
greater immune response compared to monomeric subunit peptide-based vaccines  
[33, 42]. 
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Figure 5. General structure of the LCP technology. The system incorporates; a lipid core, 
a carrier or branching component and peptide epitopes. The small capital ‘n’ dictates 
modifiable length of lipoamino acids. Derivatives of the LCP system were utilized and 
reported in Chapter 4 and 5. 
 
1.4.2.2 Acrylate Polymer  
Synthetic polymers have never been intended to be used; neither as immunostimulant 
(adjuvant) nor delivery system, until recently, where the need to find strong adjuvants as 
alternatives to the classical alum based adjuvants, one of many reasons of the exploration. 
One of the earliest polymers studied as adjuvants was polyacrylic acid (PAA). In 1998, 
Boon and co-workers demonstrated that co-administered of PAA with inactivated 
Newcastle disease virus was able to induce significant immune response in chicken [43]. 
Esterification of the free carboxylic acid groups on the PAA side chains using octanol and 
butanol attachments further increased the antibody titres [43]. Assessments on the 
capabilities of the modified PAA as an alternative adjuvant showed that the alkyl esters 
were able to enhance immunoglobulin A (IgA) secretion against influenza virus stain MRC-
11, haemagglutinin/neuraminidase subunit of influenza virus strain A/Texas, and bovine 
serum albumin [44]. However, one noticeable disadvantage of the use of Boon’s adjuvant 
was the lack of chemical analysis (quality and purity) of the synthetic adjuvant, although a 
fully characterized compound is one of the prerequisite for synthetic vaccine development; 
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as requested the US Food and Drug Administration [45]. The development of another PAA 
derivative, poly(t-butyl)acrylate or PtBA via atomic transfer radical polymerization (ATRP) 
technique, which was initiated by Matyjaszewski group, possess an advantage over 
Boon’s PAA derivatives. The PtBA synthesized via ATRP method is well characterized 
(high quality and purity) with polydispersity index of less than 1.12 (value of 1 represent 
monodispersed constructs) [46, 47]. Successively, more derivatives of PtBA were 
reported, among which were the star and dendritic type PtBA polymers  
(Figure 6) [48, 49]. These star and branched PtBA polymers can be further modified to 
accommodate multiple antigenic components, and thus can be used as the core for a 
vaccine construct [49]. 
 
Figure 6. General structure of a (A) linear-, (B) star-PtBA reported in Chapter 3. 
 
1.5 Formulation into Nanoparticles 
It was revealed that vaccine efficacy does not only depend on the biochemical composition 
of the immunogens (vaccine constructs) but also their morphological properties, such as 
particle size, plays a role in the induction of immune response [50, 51]. There are reports 
that vaccines delivered in the form of particulate: (i) are likely to be uptake by APCs for 
immune processing [52]; (ii) protects antigen from enzymatic degradation; and (iii) large 
particulates can act as depots (i.e. trapping antigen and therefore slowly presents the 
antigen to immune cells) [53] while smaller ones (<200 nm) are readily transported through 
the lymphatic system [51, 52], where many immune cells reside. These discoveries 
resulted to growing interest into the development of vaccines with well-defined particle 
sizes [33].  
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Both carriers (PtBA and LCP) reported in Chapter 3-5 were designed to possess 
hydrophobic moiety as the core construct. Conjugation of these units to hydrophilic peptide 
antigens therefore resulted in amphiphilic compounds that are able to micellize (self-
assemble) into small particulates [49, 54]. These nanoparticles vaccines could therefore 
induce significant immune responses against the targeted diseases. 
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1.6 Research aims and hypothesis 
1.6.1 Background 
Streptococcus pyogenes or group A streptococcus (GAS), Necator americanus 
(hookworm) and Schistosoma mansoni (schistosomes or blood fluke) are killing and/or 
disabling more than 500 million people throughout the globe. After multiple worldwide 
attempts to cure the infections, and decades of intensive vaccine researches, the global 
burdens are still worrisome. Although the infections are curable using antimicrobials or 
antiparasitic drugs, however, frequent reinfection occurs rapidly, especially in endemic 
areas. Moreover, there are no vaccines against these pathogens. The usage of whole 
pathogen and proteins as vaccines has led to fiasco of experimental failures, primarily due 
to reactogenic responses. Thus, development of vaccines via subunit peptide-based 
approach provides alternative approach in developing vaccines against these diseases.  
 
1.6.2 Hypothesis 
Despite many protein targets have been identified, protein-based vaccines struggles to 
elicit appropriate immune (antibody) protection against these pathogens. As an alternative 
strategy, appropriate subunit peptide-based vaccine design, coupled with the use of PtBA 
and LCP carrier systems, can be utilized as a synergic treatment regime that is able to 
provide an alternative control measure to regulate the widespread of the diseases. 
Conjugation of hydrophilic peptides to the lipophilic carriers enables self-assembly process 
to create particles that mimic natural infections. The particulates can be used as self-
adjuvanting vaccines that are able to induce desired antibody responses. 
 
1.6.3 Overall aims 
This project aimed to develop potent subunit peptide-based vaccines that could induce 
adaptive immune response (specifically IgG) against: (i) the major virulence factor in GAS, 
M protein, (ii) the hookworm’s digestive enzyme, APR-1, and, (iii) the blood fluke digestive’ 
enzyme, CatD, without the use of additional adjuvant. The self-adjuvanting vaccines would 
be able to induce protective antibodies against their target pathogens. 
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1.6.4 Specific aims 
1.6.4.1 The first aim was to establish synthetic and self-assembly pathway for vaccine 
development against GAS based on J14 peptides conjugated to dendritic and linear PtBA. 
This aim included: 
• The synthesis and purification of vaccine component: the J14 peptide epitope and 
its azide analogue. 
• The optimization of J14-polymers conjugation via copper catalyzed azide-alkyne 
cycloaddition (CuAAC) and the self-assembly process of the product to form 
nanoparticles. 
• Physicochemical characterizations of the nanoparticles including analysis of the 
peptide conformation, particle size and peptide substitution ratio on polymer. 
• Efficacy analysis of the nanoparticles to produce antibodies in mice.  
 
1.6.4.2 The second aim was to design, synthesis and characterize subunit peptide-based 
vaccines based on APR-1 protein for vaccines against Necator americanus. This aim 
included: 
• Utilization of bioinformatics tools to design epitopes that possessed similar 
conformation to the native protein-sequence. 
• The synthesis of the designed peptides and its LCP variant via stepwise solid phase 
peptide synthesis (SPPS) or CuAAC.  
• Optimization of: (i) the CuAAC reaction for the peptide-LCP conjugation; (ii) the self-
assembly of the products into nanoparticles. 
• Physicochemical characterizations of the self-assembled nanoparticles including 
analysis of the peptide conformation and particle size. 
• Antibody production studies in mice. 
 
1.6.4.3 The third aim was to develop improved vaccine candidates against Schistosoma 
mansoni via epitope re-design and incorporation of a universal T-helper epitope (P25) 
approaches. This aim includes: 
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• The use of bioinformatics tool to design new peptide epitopes. 
• The synthesis of LCP vaccine candidates. Additionally, a promiscuous T-helper 
epitope was conjugated to each vaccine candidate. 
• Physicochemical characterizations of the self-assembled nanoparticles including 
analysis of the peptide conformation and particle size. 
• Evaluation of antibody production in mice. 
 
1.7 Thesis outline 
The following chapters include a review article (Chapter 2) and published (Chapter 3) or 
submitted manuscripts (Chapter 4 and Chapter 5) of the research data. The final chapter 
includes conclusions derived from experiments and suggestions for future undertakings. 
Chapter 2 reviews the flexibility of the CuAAC reaction as a method for biochemical 
conjugation of peptides and proteins. This chapter covers fundamental introduction to the 
reaction and examples of its application in various fields and applications. The beauty and 
the versatility of the CuAAC reaction make it the most suitable bioconjugation method for 
vaccine development.  
Chapter 3 comprises published article describing the synthesis, characterization and 
immunological assessment of two peptide-polymer vaccine candidates against GAS. In 
this chapter, the synthesis of the peptide and polymers building blocks, the conditions for 
the bioconjugation, and the self-assembling procedures are described. The ability of the 
vaccine candidates in inducing high antibody titers after single immunization is discussed. 
The size-dependent response of the vaccines is also reported. Based on this study, the 
polymers were found to be excellent self-adjuvanting carrier systems that are able to 
induce strong and rapid antibody responses. 
Chapter 4 includes submitted manuscript that describes the importance of the epitope 
design and selection of delivery systems for the development of peptide-based vaccines 
against hookworm parasite. This paper also describes an alternative method to design 
conformational-active epitope as the mean to improve peptide conformation. Additionally, 
the synthesis, characterization and immunological assessment of the vaccine candidates 
are reported. Interesting discussion around expected and predicted immunological 
response is also presented. 
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Chapter 5 is a submitted manuscript around the design, synthesis and immunological 
evaluation of vaccine candidates against schistosome parasite. The application of 
computational tools to design conformational-dependent epitope is also presented in this 
chapter. As a follow-up to a previously published manuscript by Toth’s group, this chapter 
focuses on the influence of the addition of a helper T cell epitope in stimulating antibody 
production. Based on this study, sacrificing a copy of a B cell epitope to accommodate a 
helper T cell epitope is favorable and that immunological property of a vaccine is best 
envisaged via in vivo studies than in silico calculations. 
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Chapter Two 
Review of Literature 
 
 
 
 
 
 
 
 
 
 
 
 
“Peptide conjugation via CuAAC ‘click’ chemistry” 
 
Ahmad Fuaad, A. A. H.; Azmi, F.; Skwarczynski, M.; Toth, I. Peptides Conjugation via 
CuAAC ‘Click’ Chemistry. Molecules, 2013, 18(11), 13148-13174. 
 
 
 
2.1 Introduction to this publication 
This chapter was published in Molecules as a review article. The CuAAC reaction is highly 
selective to azide and alkyne functional groups but it is highly versatile and easy to work 
on. The reaction is a promising strategy as an alternative method to conjugate biological-
sensitive compounds. Furthermore, the formation of the amide bond isoster,  
1,4-disubstituted triazole moiety, makes CuAAC a suitable auxiliary for the amino acid 
linkage. Examples of the application of CuAAC in various fields are presented.  
 
 
2.2 Reprint of article in Molecules publication format 
Molecules 2013, 18, 13148-13174; doi:10.3390/molecules181113148 
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Abstract: The copper (I)-catalyzed alkyne azide 1,3-dipolar cycloaddition (CuAAC) or 
‘click’ reaction, is a highly versatile reaction that can be performed under a variety of 
reaction conditions including various solvents, a wide pH and temperature range, and using 
different copper sources, with or without additional ligands or reducing agents. This 
reaction is highly selective and can be performed in the presence of other functional 
moieties. The flexibility and selectivity has resulted in growing interest in the application 
of CuAAC in various fields. In this review, we briefly describe the importance of the 
structural folding of peptides and proteins and how the 1,4-disubstituted triazole product of 
the CuAAC reaction is a suitable isoster for an amide bond. However the major focus of 
the review is the application of this reaction to produce peptide conjugates for tagging and 
targeting purpose, linkers for multifunctional biomacromolecules, and reporter ions for 
peptide and protein analysis. 
Keywords: CuAAC; click chemistry; chemical ligation; peptide ligation 
 
1. Introduction 
Peptides and proteins were discovered in the beginning of the 20th century. However, it took more 
than 50 years for scientists to understand their natural biosynthesis pathway. In cells, the biosynthesis 
of peptides and proteins starts with the transcription of deoxyribonucleic acid (DNA) sequences to 
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ribonucleic acid (RNA) sequences, which is also known as messenger RNA (mRNA). These mRNA 
transcripts are translated into peptides or proteins in the ribosome. In this biological ‘mechanical’ 
ligation factory within living cells, amino acids are conjugated to one another with the help of transfer 
RNA (tRNA). The resultant proteins perform crucial roles in living organisms, serving as enzymes, 
structural proteins, signaling proteins etc. The broad spectrum of biological activities has made 
proteins an attractive component of modern pharmaceutics. For example, insulin,used as a drug to 
control blood sugar level in patients with Type 1 diabetes, was originally extracted from cows and 
pigs, purified and used in humans as a therapeutic drug [1]. To improve this process, scientists have 
tried to mimic the conjugation process in vitro. Chemical peptide synthesis began when Theodor 
Curtius succeeded in conjugating the first N-protected dipeptide, benzoylglycylglycine, in 1881 [2]. 
Twenty years later, Emil Fisher published an alternative glycylglycine dipeptide synthesis via a 
hydrolysis pathway [3]. Since then, interest in peptide synthesis grew and with the introduction of 
temporary protecting groups such as carbobenzoxy (Cbz) by Bergmann and Zerwas in 1931 [4], the 
synthesis of the first biologically active peptide hormone (oxytocin) was accomplished by Vigneaud et 
al. [5]. Finally, peptide synthesis was streamlined with the introduction of solid support (also called 
solid phase peptide synthesis or SPPS) by Merrifield in the early 1960s [4,6]. The SPPS approach 
allowed the synthesis of complex, chemically synthesized biological active peptides such as human 
insulin and ribonuclease A enzyme [4,7]. Peptides up to 50 amino acids in length can be efficiently 
synthesized by SPPS in a relatively short time. Major drawbacks of SPPS were observed for the 
synthesis of longer peptide (>50 amino acids) where the solubility of the growing peptide and 
accumulation of by-products on the solid support resulted in poor purity and yield [6]. 
New chemical synthesis techniques were then developed to combine two or more peptide fragments 
to form a longer construct. For example, Kimura et al. in 1981 used a segment condensation reaction 
technique where 13 fragments of five amino acid long peptides (each with protected side chain) were 
conjugated together in water to form a functional protein [8]. This reaction is typically limited by 
epimerization of enantiomerically active residues at the C-terminus of the peptide during carboxyl 
group ‘activation’ prior to the condensation reaction. Additionally, the presence of protected side 
chains was required to avoid by-product formation due to the reaction of side chain functional groups. 
The method was extremely tedious and produced a very poor yield of the final product. 
In the same year, a “prior thiol capture” reaction was introduced by Kemp et al. The group reported 
intramolecular O,N-acyl transfer with disulfide interchange to transfer an adjacent acetyl group to an 
amine group at the N-terminal of a cysteine peptide residue, illustrated in Scheme 1 [9]. However, the 
method has its own limitations: new disulfide bond formation is slow and the whole process resulted in 
the formation of byproducts. 
A more advantageous chemical technique called native chemical ligation (NCL) was introduced by 
Wieland et al. in 1953. However, a practical method was not reported, until Kent and co-workers 
introduced their developments on the technique in the 1990s [6,10,11]. NCL involves the conjugation 
of a C-terminal thioester peptide to an N-terminal cysteinyl peptide (Scheme 2). This technique was 
much more efficient in comparison to the approaches previously mentioned, as protection of peptide 
side chains was not required and final product was produced in high yield and purity. However, the 
peptide of interest needed to contain a cysteine residue (or its derivatives) within its native sequence, 
otherwise additional process of desulfurization is required to remove the ‘unwanted’ sulfur group [11,12]. 
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Consequently, during the desulfurization, other sulfur moieties within the peptide construct, if present, 
must withstand the desulfurization process or else, the sulfur groups will be removed and will resulted 
in undesired peptide construct [12]. Although NCL is an exceptionally effective method for the 
production of large peptides and proteins, there were also difficulties encountered during the ligation 
of hydrophobic target products [13,14]. Additionally, NCL has also been difficult to apply as a 
conjugation technique between peptides and non-peptidic molecules such as polymer. Thus alternative 
methods such as Staudinger ligation, Diels-Alder reaction, strain promoting alkyne-azide cycloaddition 
(SPAAC) and copper catalyzed alkyne-azide cycloaddition reaction (CuAAC) have been developed 
for further modification of peptides modification. 
Scheme 1. Prior thiol capture involving intramolecular O,N-acyl transfer reaction.  
(A) Activated thiol species (B) captured thiol fragment, and (C) after acyl transfer reaction, 
(D) desired peptide is formed. 
 
Scheme 2. An example of NCL reaction of peptides containing cysteine or its derivatives. 
Reaction (A) intermolecular thioesterification; (B) intramolecular SÆN acyl transfer;  
(C) (optional) desulfurization of cysteine derivatives to cysteine residue. 
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This review presents advances in the conjugation of peptides to other biomolecules via CuAAC to 
form 1,4-disubstituted 1,2,3-triazoles. CuAAC is used as an alternative to NCL, the bioconjugation 
technique widely used in protein and peptide chemistry. This review briefly described the history  
of CuAAC and the structural similarities of triazole to amide bond, and later presents most  
recent application of CuAAC as linkers and amide bond isosteres. Additional reviews in regards to 
NCL, Staudinger ligation, Diels-Alder reaction and SPAAC reactions were recently appraised by 
Chandrudu et al. [15] and Raibout et al. [16], van Berkel et al. [17], de Araujo et al. [18], and  
Debets et al. [19], respectively. 
2. Copper (I) Catalyzed Alkyne-azide 1,3-Dipolarcycloaddition (CuAAC) 
The formation of triazole was first discovered and reported by Authur Michael in 1893 [20].  
In 1961, Rolf Hüisgen performed systematic studies on the nature of this reaction which was 
subsequently named the 1,3-dipolar cycloaddition (Scheme 3) [21]. The use of copper for the catalysis 
of Hüisgen azide-alkyne 1,3-dipolarcycloaddition (CuAAC), was first reported by L’Abbé in 1984 as a 
side reaction during the synthesis of azidoallenes complex [22]. No further investigation related to this 
observation was performed until in 2001, when the reaction was introduced by two independent 
laboratories led by Sharpless in the US and Meldal in Denmark [23,24]. CuAAC reaction, or ‘click’ 
reaction, is a regioselective copper (I) catalytic reaction between two terminal alkyne and azide 
functional groups, that give rise to 1,4-disubstituted 1,2,3-triazoles under mild conditions (Scheme 3, 
detailed possible mechanisms were discussed by Jones et al. and Himo et al.) [25–28]. Soon after its 
discovery, the CuAAC reaction became a common conjugation method, predominantly because this 
reaction is very robust, selective, and insensitive to the changes in pH and temperature. Currently, 
CuAAC is used in a wide range of applications in various disciples ranging from biomolecular and 
medicinal chemistry to polymer sciences [29–31]. 
Scheme 3. General reaction for CuAAC reaction producing a triazole ring. 
 
Although the use of copper (I) is crucial for the cycloaddition reaction, in some cases, regulation of 
solvent and temperature (by heating in oil bath or microwave irradiation [32,33]), and introduction of 
ligand molecules or reducing agent can further push the reaction towards its desired product. Many 
copper (I) sources were tested and reported to catalyze the reaction. These include: copper (I) iodide 
(CuI), copper (I) bromide (CuBr), copper (II) sulfide (CuSO4) or copper (0) (such as copper wire, 
powder and palette). For example, Meldal and co-workers used CuI and N,N-diisopropylethylamine 
(DIPEA, base to pre-activate the CuI by forming a copper-acetylene complex) in N,N-dimethylformamide 
(DMF) at 25 °C to yield 1,4-disubstituted 1,2,3-triazole structures [24]. An alternative method reported 
by Jang et al. involved the introduction of sodium ascorbate (NaAsc, a reducing agent that converted 
in situ copper (II), CuII, into copper (I), CuI) and substitution of DIPEA with pyridine also resulted in 
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formation of the triazole structure [34]. It was reported that removing the base from the reaction 
mixture usually did not significantly influence the reaction yield, thus base-free CuAAC is often 
reported [30,35,36]. The optional introduction of a copper ligand helped to enhance the progress of the 
reaction while protecting the CuI ions from oxidation. The versatility of this cycloaddition reaction was 
recently reviewed by Meldal [37]. 
Nevertheless, the application of CuAAC for biological compounds is controversial in regards to 
copper toxicity and the use of the reducing agent. For example there were reports that active copper 
species readily form radicals that can (partially) degrade or destroy peptides and protein complexes 
during CuAAC reactions, while in in vitro system, copper complexes may be taken up by cells, thus 
altering cellular metabolisms and functions [38,39]. To overcome these limitations, CuAAC-cell 
compatibility can be improved by either, the use of water-soluble ligands (e.g., bis-(L-histidine) [40]) 
or, in some cases, the use of accelerating CuI-ligands that allowed low CuI loading during catalytic 
reaction [41]. It has been also shown that copper wires can catalyze CuAAC reaction without need of 
the use of any additional ligands or reducing agents [30,42–44]. The toxicity of copper is well 
established; however, at the same time copper is essential element for human health, therefore the level 
of copper traces presented in the biologically relevant material need to be precisely determined (the 
recommended health standard level of copper is below 15 ppm) [45]. 
3. Structural Studies of Amide Bond and 1,4-Disubstituted Triazole 
Amide bonds play a very important role in determining the bioactivity of a protein. Amino acids, 
the building block for proteins, are connected via the amide bonds. These bonds have restricted 
flexibility which allows distinct protein conformation. This structural conformation is further enhanced 
by intramolecular interaction between neighboring peptide chains as a result of hydrogen bonding, 
disulfide bridge formation, or hydrophobic interactions [1]. Turns in the backbone and intramolecular 
bonding result in proteins adopting a stable conformation (Figure 1). As a result, the incorporation of a 
single amino acid substitution at any point within the protein may result in altered structure. Thus, 
when an unnatural element is incorporated into peptide or protein, the ability of the synthetic 
constructs to mimic the native structure is very important to ensure the synthetic constructs maintain 
the desired biological activity. For example, it was discovered that single amino acid substitution in a 
synthetic luteinizing hormone releasing hormone (LHRH) drastically changes the peptide folding thus 
reduces the its activity [46,47]. Similarly, an antigen in subunit peptide vaccine needs to fold into its 
native conformation in order for the immune system to be able to recognize it and thus to produce a 
protective antibodies against the desired pathogen [48]. 
The importance of peptide and protein conformation limits the ability to easily substitute peptide 
bonds with unnatural elements. Peptide bonds can be replaced by mimicking functional groups  
(e.g., ester) [49,50]; however, not all of them, when incorporated in the sequence, are able to maintain 
secondary structure of the peptide (e.g., alkene) [51]. These facts prompted special interest in the 
application of triazole moiety for this purpose. The structural studies of amides and triazoles were first 
performed by Horne et al. in 2004 with the modification of pLI-GCN4 sequences, an α-helix coiled 
coil structure. They reported that although triazole substitution of the amide bond in a peptide 
backbone is longer by 1.1 Å (Figure 2), the modified peptide was still able to maintain its helical 
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structure [52]. Later, Brik et al. supported the idea that the 1,4-disubstituted triazole ring is suitable as 
a peptide surrogate or bioisostere [53]. The group experimented with triazole analogs of a peptide-based 
HIV protease inhibitor and found that the modified constructs maintained nanomolar inhibition 
activity. Crystallographic analyses of the constructs showed that the analogs were bound to the same 
enzyme pocket as the parent peptide. This finding further supported the observation that the triazole 
group displayed similar configuration to amide bond, mimicking trans-amide bond arrangement 
(Figure 2). Moreover, the triazole structure conferred almost similar polarizing properties to those found 
in amides, including the positions of hydrogen bonding donor and acceptor, and the similar 
electrophoretic dipole (5 Debye as compared to 4 Debye in amide bonds) [53]. In addition, the triazole 
ring is able to align itself with other amide groups via hydrogen bonds, in a similar manner to the 
alignment of an amide group to other amides in peptide secondary structure. The ring also adapted a 
three dimensional planar structure similar as an amide bond (Figure 2) [54–56]. However, unlike a 
native amide bond, triazoles are stable against proteolytic amide degradation. In sum, it is profound 
that structural modification of peptides and proteins using the CuAAC reaction could form an effective 
structural mimic of native amide bonds.  
Figure 1. From amino acids to protein. (A) free amino acids; (B) primary structure 
(peptide bonds); (C) secondary structure (α-helix or β-sheet); (D) tertiary structure (whole 
protein or subdomain protein); (E) quaternary structure (multiple domain protein, HIV 
Protease, Protein Data Bank (PDB) number = 1HSG) [57].  
 
Triazoles have been found to be excellent peptide bond substituents mainly due to their ability to 
increase peptides’ biological stability in vivo while maintaining their activity. The natural occurring 
amide bond is very susceptible to various proteases [58]. Thus, substituting the amide bond with a 
triazole provides an alternative prospect to increase the bioavailability of the target compound in vivo. 
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The other advantage of triazole substitution is related to the CuAAC reaction itself. Unlike peptide 
coupling reactions, CuAAC is selective towards terminal azide and alkyne functional groups. This 
reaction can therefore be performed on unprotected peptides containing azide/alkyne groups [43]. 
Moreover, the CuAAC reaction is easy to perform with an ample range of reaction media and copper 
sources to choose from. Hence, the reaction condition can be altered to suit the conditions of the 
conjugation reaction. Despite the versatility of CuAAC and the triazole moiety mimicry of the amide 
bond, in most cases, CuAAC is primarily used for peptide-to-biomolecular conjugation. 
Figure 2. Triazole as amide bond bioisosters. Arrow (    ) represent hydrogen bonding 
sites. (PDB: 1HPV [59] and 1ZP8 [53]). 
 
4. Application of CuAAC in Peptide Modifications 
In 2002, the first application of the CuAAC reaction to form peptide derivatives was reported  
with the synthesis of peptidotriazoles and neoglycopeptide-linked-triazoles on solid support by  
Tornoe et al. [24]. A wide variety of azido groups were tested, affording compounds with crude 
purities ranging from 75% to 99% (Figure 3) [24]. The application of this reaction is not limited to 
conjugation between molecules (intermolecular coupling), but also within molecules (intramolecular 
coupling), thus the number of publications that have used this method have grown exponentially. Both 
inter and intramolecular conjugations have recently been added to the vast number of applications for 
this technique. 
4.1. Intermolecular Linker 
4.1.1. Single-Site Intermolecular Linker 
One of the purposes of azide-alkyne single scaffold conjugation is tagging biomolecules. By 
labeling the peptides or protein with radioactive molecules (such as iodine-125 or fluorine-18 and their 
derivatives) or fluorescent compounds (green fluorescent protein, GFP), the target of interest can be 
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visualized via positron emission tomography (PET) or fluorescent imaging (fluorescent microscopy), 
respectively [60–65]. 
Figure 3. Examples of resin-bound peptidotriazoles constructs synthesized via CuAAC. 
 
One example for such radiolabeled conjugation was to tag the tumour-targeting high molecular 
weight peptide, “pH (low) insertion peptide” (pHLIP) with radioactive 18F. Direct labeling of large 
peptide using 18F was synthetically challenging due to: 
(1) Short half-life (low stability) of 18F—thus the synthesis needed to be completed within a  
short time; 
(2) Consideration of the safety of the operator working on the high gamma energy 18F; 
(3) Low purity resulting from direct coupling of 18F, while the use of 18F derivatives often required 
longer and more complicated synthetic procedures [66–68]. 
Although direct 18F labeling was possible [65], however, the functional group in the peptide is 
barely compatible. Thus, CuAAC approach provides the best alternative for such conjugation to occur. 
Sutcliffe and co-workers successfully synthesized a 20 amino acids αvβ6 18F-radiolabeled peptide 
(medium MW ~2,000 Da, 10% yield) via the CuAAC reaction. However, the group experienced major 
difficulties when trying to conjugate the radiolabelled group to larger peptides via CuAAc [61,63]. A 
method to overcome this problem was reported by Daumar et al. who synthesized and conjugated a 
novel 18F derivative to the pHLIP peptide via CuAAC reaction [61]. The initial CuAAC reaction 
between the 18F-polyethylene glycol (PEG)-alkyne and pHLIP-azido groups under standard conditions 
(with copper (II) acetate, NaAsc in H2O/MeCN (1:1 mixture) at 70 °C) was unsuccessful, despite the 
fact a similar reaction between 18F-PEG-alkyne and RGD-azide peptide (MW ≈ 2,000 Da) proceeded 
smoothly [61,69]. Radiochemically active 18F-pHLIP was obtained using a novel 18F-alkyne prosthetic 
group (18Fluoro-pyridine alkyne) under standard conjugation conditions (13% pure yield within 85 min 
of preparation time) [61]. The use of less polar solvent mixture, i.e., ethanol in H2O (1:1), was 
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preferable for the CuAAC reaction of the 18F derivative and pHLIP as compared to in H2O/MeCN 
(1:1) mixture [61]. 
Octreotide is a peptide that has high receptor specificity to somatostatin receptors overexpressed in 
neuroendocrine tumours. The Reubi’s group was the first to investigate somatostatin reception via a 
radiolabeled octreotide analog, [Tyr3]octreotate (TOCA) in 1985. The labeling was performed by 
iodination reaction at the tyrosine (Tyr3) side chain [65]. Conversely, the CuAAC reaction was used by 
Aboagye and colleague to conjugate a different radioactive compound (18F) to the TOCA analog 
(Figure 4) [63]. Aboagye’s group was the first to illustrate the application of CuAAC for tagging 
molecules through the conjugation of octreotide and a radioactive 18F compound (instead of direct 
labeling of an amino acid within the construct). With the primary aim of reducing the synthesis time 
and increase TOCA binding affinity, five compounds were prepared using different alkynes analogs  
to create a novel library of radiolabeled TOCA analogs. The CuAAC synthesis using CuSO4 (2 eq.)  
and NaAsc (2.2 eq.) at pH 5.0 at room temperature resulted in over 98% yield for two out of five 
compounds (3 and 5). Optimizing the reaction conditions by increasing the amount of CuSO4 to  
4 eq. and NaAsc to 4.4 eq. resulted in excellent yield (>98%) for the other three compounds (1, 2 and 
4). The group suggested that the position of the alkyne group located next to the amide group (3 and 5) 
enhanced the kinetics of the CuAAC reaction, while sequential glycol groups near the alkyne moiety 
reduced the CuAAC reaction rate (1) [63]. More detailed study into the influence of functional groups 
on the CuAAC reaction was reported by Golas et al. [70] and Fokin and Hein [71]. Affinity binding 
experiments with Reubi’s compounds illustrated high binding affinity (IC50 < 10 nM) compared to 
control octreotide peptide (IC50 = 15 nM) [63]. This indicated high specificity of the compounds for 
the somatostatin receptor (CuAAC reaction did not cause loss of binding capacity). 
Figure 4. 18F-labeled TOCA analogs for tumor imaging. CuAAC condition: pH 5 acetate 
buffer, DMF and acetonitrile (MeCN) (8:3:10) at 25 °C plus; CuSO4 and NaAsc. 
 
Sewald and colleagues used arginine-aspartic acid-glycine (RDG) peptide as a targeting moiety  
for anticancer drug delivery [72]. The CuAAC reaction was used to conjugate cyclic RDG peptide  
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to cryptophycins, an apoptosis promoting and tubulin inhibitor depsipeptides (anticancer drug). 
Unfortunately, conjugation of RDG to cryptophycins reduces the drug’s efficacy. Addition of 
fluorescein derivative to the drug further decreased its affinity to the microtubule in cancer cells due to 
steric hindrance. However, confocal analysis of the fluorescein-labeled constructs found that the 
presence of the cyclic peptide correlated with increased endocytosis by tumor cells. This illustrates  
the possibility to use the RDG peptide as a tumor-targeting moiety in peptide-drug conjugates. The 
CuAAC reaction was performed using copper (0) powder in tert-butanol/H2O (2:1) mixture at room 
temperature. Copper powder was selected because solid copper is easily removed by filtration. The 
product yield was moderate with 68% and 43% yield for the non-fluorescent and fluorescently-labeled 
compounds, respectively, possibly due to short reaction time (~8 h) and the use of copper solid without 
a ligand [72]. 
Besides tagging, the CuAAC reaction was also used to modify the biological properties of  
peptide-oligonucleotide conjugates (POCs). Astakhova et al. conjugated enkephalin peptides to 
oligonucleotide (deoxyribonucleic acid, DNA) via CuAAC reaction to form POCs and the structure 
and properties of the oligonucleotides were examined [29]. The POCs were synthesized using CuSO4 
in the presence of tri(benzyltriazolylmethyl)amine (TBTA) ligand (1:1), NaAsc, aminoguanidine 
hydrochloride, dimethylsulfoxide (DMSO), 0.2 M carbonate buffer at pH 8.5, under argon atmosphere 
with vortexing for 12 to 24 h at room temperature [29]. The conjugation yields were over 95% and the 
method was highly reproducible. Thermal denaturing temperature (Tm) analysis showed the POCs 
remained stable at higher temperatures (up to 10 °C higher) than free oligonucleotides. Structural 
analysis of double POC conjugates resulted in structural stability of the POCs for up to 8 h in diluted 
human serum (90%) in comparison to a locked-nucleic acid DNA (locked-DNA) and unmodified 
DNA (control), which were degraded within 1 h and 30 min, respectively (Figure 5) [29]. 
Figure 5. Structural comparison between; (A) CuAAC locked-DNA; (B) locked-DNA; and 
(C) unmodified DNA. Red structures highlight the DNA backbone. 
 
Furthermore, to improve the efficiency of fluorinated organophosphorous inhibitor (floronated OPI) 
targeted against serine hydrolases, Sokolova et al. constructed a library of small peptide analogs 
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conjugated to the inhibitor via CuAAC reaction (Table 1) [73,74]. Preliminary reactions were 
performed with CuSO4 and NaAsc in chloroform (CHCl3)/H2O at 10:1 mixture for 1 h at 40 °C. 
However, the yields were relatively modest (30%–65%) [74]. Prolonged reaction time (3 h) in 1:1 
CHCl3/H2O mixture improved the overall yield to over 75% [73]. Significant inhibition of the 
fluorinated OPI-peptide conjugates was observed (IC50 in milimolar range) with selective inhibition 
towards BChE and CaE subtype serine hydrolases [74]. 
Table 1. Selected fluoronated OPI-peptide constructs linked via CuAAC reaction. 
 
Entry R′ R1 R2 R3 R4 R5 Yield (%)
1 -CF3 -CH3 -CH3 -CH3 
 
56 
2 -CF3 
 
-H -H 
 
40 
3 -CF3 
 
-H -H Bn -CF3 45 
4 -CF3 -H -CH3 -CH3 Bn -CF3 45 
5 -C(O)OCH3 i-Pr -H -H Bn -CF3 65 
6 -C(O)OCH3 i-Pr -H -H Bn 
 
55 
Aggregation of elongated peptide during SPPS is often associated with poor yield and purity of the 
product [75]. With the aim to study the aggregation property of peptides, Perrier and colleagues 
worked with Alzheimer’s disease-associated β-amyloid peptide (Aβ), which is known for its extreme 
aggregation, as a model peptide. The group used a microwave-assisted CuAAC reaction to conjugate short 
Aβ fibrils (sequence 16–20, FVLKFF) to different amphiphilic polymers: polar poly(hydroxylethyl 
acrylate) (PHEA20), and less polar poly(N-isopropyl acrylamide) (PNIPAAM20) [76]. Microwave-assisted 
CuAAC was chosen to destabilized peptide aggregation and further enhanced the CuAAC reaction. 
The reactions were performed using CuSO4, NaAsc and DMF at 100 °C for 15 min. After completion of 
the conjugation, excess alkyne was removed by a secondary CuAAC reaction with the resin-bound azide. 
The final pure peptide-polymer conjugates were obtained in 43% yield. TEM images illustrated different 
structural assemblies which were highly dependent on aggregation time and concentration of the CuAAC 
products [76]. Attachment of the polymers generally disturbs the Aβ aggregation. For example, in the 
case of PHEA20-Aβ conjugates, an 80% reduction in β-sheet formation was observed [76]. 
More recently, Brimble and colleagues synthesized novel Pam2Cys constructs by conjugating 
Pam2Cys to MUC1 peptide via CuAAC reaction (Figure 6) [77]. The CuAAC reaction was performed 
using CuI/ triethylphosphine (P(OEt)3)/DIPEA in DMF for 30 min at room temperature [77]. 
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Figure 6. (A) synthesis of azide modified Pam2Cys via four steps: (i) piperidine, 
dichloromethane; (ii) imidazole-1-sulfonyl azide, potassium carbonate, methanol;  
(iii) palmatic acid (Pam), diisopropylcarboiimide, dimethylaminopyridine, tetrahydrofuran; 
(iv) trifluoroacetic acid; (B) CuAAC reaction of Pam2Cys construct. 
 
4.1.2. Multiple-Sites Intermolecular Conjugates 
The CuAAC reaction allows single site conjugation between two molecules. However, multiple 
molecules can also be specifically conjugated to a single multi-site entity, and two molecules can be 
associated together using multiple conjugations. 
Multiple biomolecule conjugation can be sub-categorized into dendritic, linear, cyclic or cross-linked 
assemblies (Figure 7). Although these conjugations are typically used in medicinal chemistry, 
dendrimer and linear assemblies have also been used in the field of vaccine development to enable 
antigen incorporation in a multiple antigen presenting (MAP) system. This system was shown to 
induce better immunological responses than a single antigen presenting system [78]. SPPS technique 
has been employed to synthesize MAP-based constructs. However, the peptides produced are usually 
difficult to purify to homogeneity. NCL of successive antigens is laborious, and attaching several 
epitopes at once can be difficult [13,14]. CuAAC provides an alternative to both stepwise SPPS and 
NCL to efficiently produce such constructs. In contrast to multivalent NCL, CuAAC proceeded faster, 
resulted in a higher yield, and the triazole product was stable in a biological environment [79]. 
Gupta et al. and Skwarczynski et al. exploited α- and ε-amino groups in the amino acid lysine as a 
branching unit for multiple conjugation sites for antigen presentations [43,79–81]. Using this technique, 
a set of azide- or alkyne-modified peptides were selected and conjugated to another peptide core. 
Conjugation efficiencies above 95% have been reported for CuAAC between functionalized azide and 
alkyne peptides. Skwarczynski et al. performed the CuAAC reaction in DMF, using copper wire as the 
copper source and heating at 50 °C without additional base, reducing agent or ligand. Within five 
hours, a 100% conversion was observed (Figure 8A) [43]. An alternative reaction was performed by 
Gupta et al. where CuSO4 and NaAsc were used for the CuAAC reaction at room temperature. 
Quantitative conjugation for a less sterically hindered peptide alkyne was attained in a shorter time  
(1 h, Figure 8B) [79]. Both constructs were found to be immunologically active in an animal (murine) 
model, signifying the compatibility of CuAAC with multiple conjugate linkers [43,79,80]. 
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Figure 7. Multiple conjugation strategy using CuAAC approach; (A) dendritic, (B) linear, 
(C) cyclic, (D) cross-linked. 
 
Figure 8. Example of multiple triazole scaffolds synthesized via CuAAC;  
(A) lipid core peptide (LCP), (B) dendron scaffold, and (C) polymeric dendrimer. 
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As an alternative, Toth and colleagues conjugated multiple copies of peptide antigen based on 
group A streptococcus M protein and human papillomavirus-16 E7 peptide to polymer cores in two 
separate experiments [31,42,44,82]. The reaction was performed in DMF, using copper wire as the Cul 
source (as a result of comproportion reaction of copper ions) and heating at 50 °C overnight [25,83]. 
Based on elemental analysis of the resulting products, the efficiency of the CuAAC reaction  
was relatively good with a substitution ratio of around 75% (Figure 8C) [31,42,44,82]. The product 
self-assembled into particles which induced strong and antigen-specific cellular [44] and humoral 
immune responses [31,42,82]. 
Perrier and colleagues examined CuAAC conjugation efficiency between a cyclic β-sheet  
forming peptide and poly(butyl)acrylate (PBA) polymer [84]. The group observed steric effects that 
limited the reaction efficiency [84]. The conjugation was carried out using two- and four-arm cyclic 
functionalized peptides as illustrated in Figure 9. CuAAC reaction was performed using CuSO4, 
NaAsc in either: DMF, trifluoroethanol (TFE), hexafluoroisopropanol (HFIP), TFE/DMF mixture,  
or HFIP/DMF mixture, and irradiated under microwave at 100 °C. Conjugation of polymers with  
high degree of grafting and polymerization (DP = 108) with a four-arm peptide showed a maximum  
of 55% conjugation efficiency. However, quantitative efficiency was reported using lower DP 
polymers (16 and 36) [84]. Reduced coupling efficiency observed by Skwarczynski et al. during the 
polymer-peptide conjugation may also result from steric effects associated with the large hydrophobic 
polymeric block [31,44]. 
Figure 9. Cyclic peptides scaffold for CuAAC bioconjugation with PBA polymer:  
(A) two-arm cyclic peptide, (B) four-arm cyclic peptide. 
 
Arora and co-workers used triazoles as substitutes for native peptide backbone (triazolamer) [85,86]. 
A fully triazole-based peptide backbone was synthesized by the group after careful optimization of the 
reaction (Figure 10A) [85,86]. The group exploited one-pot triazole synthesis via sequential zinc (II) 
catalyzed diazoltransfer reaction and CuAAC reaction on solid support (PAM resin). The α-amino 
group of the amino acid was substituted with an azide moiety using amino acid methyl ester, 
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trifluoromethanesulfonyl azide (triflic azide), CuSO4, and triethylamine at room temperature for three 
hours. The CuAAC reaction was performed by the addition of alkyne-derivatised α-amino acid, TBTA 
ligand and NaAsc to the initial reaction mixture and stirring at room temperature for 18 h. Upon repetition 
of above process the final product was obtained with an overall yield of 78% [85]. Interestingly, NMR 
analysis of the triazolamer suggested that the peptidomimic adopt β-strand-like structures, although the 
structural backbone lacks β-strand’s hydrogen bond functionality [87]. The group further synthesized and 
evaluated triazolamer as human immunodeficiency virus-1 protease (HIVPR) inhibitor by synthesizing 
triazolamers that superimposed L-700,417 (Figure 10B), a peptide-based inhibitor that is widely used for 
HIVPR inhibition studies [87]. Five compounds (Figure 10C) showed high binding affinity (IC50 in 
micromolar range) compared to L-700,417 (IC50 = 670 µM) illustrating the viability of the 
triazolamers as peptidomimatic inhibitor. 
Figure 10. (A) Amide backbone modification with triazole rings; (B) HIVPR inhibitor;  
(C) Triazolamer-based HIVPR inhibitors. 
 
Ghadiri and co-workers synthesized heterocyclic pseudotetrapeptide via CuAAC reactions. 
Mimicking small β-turn molecules, the constructs were used as probes to assess the conformation of 
ligands to target the somatostatin receptor [88]. These 13- or 14-membered ring constructs each bore 
one or two triazole rings as peptide backbone surrogates (Figure 11A) [88]. Initially, linear peptides 
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were synthesized in solution phase and later were subjected to CuAAC reaction (CuI, 2,6-lutidine, 
DIPEA, TBTA in MeCN, stirred at room temperature for 12 h) to produce their cyclic counterparts. For 
the initial experiment, Ghandiri and co-workers synthesized a library of 16 cyclic isomeric compounds 
containing one triazole moiety. HPLC yields of 31% to 90% were obtained. Additionally, binding 
affinity experiments were carried out for the library. Although one compound showed high binding 
affinity (IC50 < 200 nM, Figure 11B), its affinity was lower than the parent peptide, SRIF-28 (IC50 < 5 
nM, Figure 11C). Cyclic tetrapeptides without triazol moieties were not tested as the synthesis of the  
12-membered ring resulted in very poor yield [88]. 
Figure 11. (A) General chemical structures of one and two triazole constructs.  
(B) Compound exhibited best somatostatin receptor binding experiment (IC50).  
(C) Chemical structure of SRIF-28. 
 
Jagasia et al. used CuAAC as a means to form a head-to-tail cyclodimerized construct on resin 
(with intact side-chain protecting groups, Figure 12). The group investigated some properties that 
could influence the formation of the cyclodimer pseudopeptide, as oppose to a monocyclic 
pseudopeptide which was mainly the aimed for some researchers [72,73,79,89,90]. Each CuAAC 
reaction was performed using CuI, DMSO:MeCN (1:3), at room temperature for 40 h [89]. It was 
concluded that cyclization of the peptide via CuAAC can be influenced by: 
(a) The distance between the active groups (azide or alkyne) and the resin—as the distance 
increased, the yield of bicyclic product decreased; 
(b) The distance between the active groups—a minimum of six amino acids promotes 
cyclodimerization; 
(c) Solvent composition ratio—affects resin swelling and interstrand hydrogen bonding thus 
affecting the dimerization, and; 
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(d) The structural homolog of the peptide (α, β, γ etc.)—α and β homologs readily form the 
cyclodimer while γ homologs do not [89]. 
Figure 12. Head-to-tail CuAAC conjugation producing cyclodimer or cyclomonomer. 
 
An example of crosslinking using CuAAC is illustrated in Figure 13. Kim and coworkers used 
polyaspartimide derivatives to construct a biocompatible, biodegradable three-dimensional hydrogel 
network that was cross-linked via the CuAAC reaction [91]. The reaction was performed using CuBr 
in the presence of N,N,N’,N’,N’’-pentamethylenetriamine ligand. The polymer hydrogel was reported 
to form within minutes [91]. 
Figure 13. Formation of hydrogel based on multilinker conjugation via CuAAC. 
 
4.2. Intramolecular Triazoles Linker 
4.2.1. Side Chain Stapling/Macrocyclization 
Peptides and proteins fold in a well-defined conformation in order to maintain their biological activity. 
Short peptides, such as APR-1 and J14i epitopes, have very distinct well-known drawbacks including 
susceptibility to protease degradation, poor bioavailability, and a highly flexible structure [43,92]. When 
used as vaccines, these peptides were poorly recognized by the immune system, resulting in weak 
antibody production. One of possible methods to improve the conformational stability of a peptide  
is by flanking it with helix promoting sequences, (e.g., GCN4 sequences) [92,93]. Alternatively,  
a side-chain stapling method can be applied. This method introduces conformational constraints in 
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peptides via side-chain-to-side-chain conjugation to stabilize peptide conformation and further 
improving peptides’ stability against enzymatic degradation [56]. 
Previous, structural studies of 310 helix based on a 4-aminopiperidine-4-carboxylic acid (Api) and 
α-aminoisobutyric acid (Aib) rich peptide was performed by Ousaka et al. Efforts to use a  
‘locked’ 310 helix approach via olefinic bridge and p-phenylenediacetic acid bridge were unsuccessful 
due to distortion of the native helix structure caused by the hydrophobic moiety of the olefinic and 
phenylenediacetic acid linkers [94,95]. Klaveness and co-workers used the CuAAC reaction to 
perform a novel stapling strategy with a Aib-rich model peptide [56]. The CuAAC stapling strategy 
was preferable because it established a hydrophilic 1,2,3-triazole moiety in the linker [56]. The model 
peptides were cyclized using CuI, P(OEt)3, DIPEA in CH2Cl2 at room temperature for 42 h. The CuAAC 
reaction produced the desired intramoleculary-linked peptide in 83% yield. Crystallographic analysis of 
the constructs confirmed formation of a nearly perfect 310 helical peptide (angle σ2 < 2o) [56]. 
Dawson and Ingale used side-chain-to-side-chain CuAAC conjugation to construct a modified  
HIV-1 gp41 peptide structure (SLWJWFK(N3)ITNWLWYIKAibKAibKK, where J is propargylglycine, 
Pra) as illustrated in Figure 14. The side chain conjugation was performed between J and azidolysine, 
K(N3), located at 310 helix position in order to stabilize the kink formed by the tryptophan and 
phenylalanine amino acids [90]. Dawson and Ingale initially faced difficulties during the cyclization 
using CuI, 2,6-lutidine in DMSO or DMF, even after a prolonged period of time. However, changing 
the reaction system to a CuBr/2,6-lutidine/DIPEA mixture resulted in 70% HPLC yield of product 
after 18 h. Analysis of the construct via circular dichroism showed the highest helicity content (based 
on mean residue ellipticity) for macrocycles with a 17- or 18- membered ring compared to their linear 
or 15 membered ring counterparts [90]. In comparison to the 310 helix system, optimization in α-helix 
system performed by D’Ursi et al. illustrated that the best helical stabilization was achieved for 
constructs that possessed a 19 membered side-chain to side chain linkage [96]. 
Figure 14. 310 helix side-chain-to-side-chain CuAAC cyclization. 
 
More recently, Waters and Park used the CuAAC reaction to investigate the effect of cyclization  
on the structure, stability and activity of a β-hairpin tryptophan-lysine-tryptophan-lysine, WKWK 
peptide [97]. The wild type (wt) peptide was shown to be able to form β-hairpin structure, had low 
stability under protease treatment (three minutes), and was able to bind to adenosine triphosphate 
(ATP) nucleic acid [97]. The WKWK peptide was modified by placing azido and alkyl groups  
at several positions within the structure [98]. CuAAC reaction was performed in phosphate  
buffer (10 mM, pH 8), in the presence of tris-tri(methylazolyl) amine ligand, NaAsc, and 
Molecules 2013, 18 13166 
 
 
tetrakis(acetonitrile)copper(I)hexaflurophosphate at room temperature overnight. It was found that 
triazole linkage of the C-terminal side-chain to the N-terminal side-chain (Figure 15) maintained the  
β-structure more readily than the wt hairpin. Cyclization through the triazole linkage afforded 
improved proteolytic (>10 fold) and thermal stability. The ability of the macrocyclized construct to 
bind to ATP was better than its wt counterpart, with IC50 of 110 µM and 179 µM, respectively [97]. 
Figure 15. Structural improvement via side chain triazole linker. 
 
4.2.2. Triazoles as Disulfide Bridge Substitutions 
Disulfide bonds (bridges) play an important role in the integrity of folded peptides and proteins. For 
example, a 17 amino acid long antimicrobial peptide tachyplesin I (TP-1), contains two disulfide 
bridges that are crucial for correct β-hairpin folding and therefore its activity. Holland-Nell and Meldal 
used the CuAAC approach to substitute these two bridges with triazoles linkers by replacing  
two cysteines with Pra and the other two cysteines with either 2-amino-4-azidobutyric acid (Abu)  
or 5-azidonorvaline (Nva) [99]. They successfully formed correctly folded β-hairpin analogs, but  
the majority of the product was in the form of a misfolded globule-like structure (Figure 16, B:C in  
1:7 ratio), following a CuAAC reaction using CuSO4/tris(carboxyethyl)phosphine in H2O for 16 h on 
resin. Microwave assisted CuAAC shifted the triazole formation, favoring the hairpin structure (B:C in 
1:1.5 ratio). It was suggested that CuAAC reaction in an aqueous environment favored intramolecular 
hairpin folding while minimizing interchain bonding, as oligomerization was not observed at both 
conditions. Inhibition experiment (MIC) of the triazole analogs showed improved antibiotic activity 
against some bacterial species (Escherichia coli, Bacillus subtilis and Salmonella typhimurium) 
compared to wild type TP-1 peptide. 
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Figure 16. β-Hairpin structure of TP-1 peptide (in single letter amino acid code).  
(A) Native structure with two disulfide bonds. (B) Hairpin-like structure via triazole 
linkers. (C) Globule-like structure due to incorrect folding. 
 
4.3. Other Applications 
A unique application of the CuAAC reaction involves the use of a triazole moiety as a gas-phase 
cleavable linker for protein/peptide quantification under mass spectroscopy (MS)-ionization  
condition [100]. Although triazole is known for its stability as peptide/protein linker [101], Sohn et al. 
showed that it could be cleaved during MS measurement and form ionized species (reporter ion) 
which, in turn, was easily recorded by an ion detector (Figure 17). The CuAAC reaction to produced 
labeled peptide was performed using; CuSO4, NaAsc, TBTA, in DMSO/H2O mixture, at room 
temperature for 4 h (yield = 69%–72%) [100]. 
Figure 17. Gas phase fragmentation of triazole into reporter ion. 
 
5. Conclusions 
The structural conformation of peptides and proteins are crucial for their biological activity. 
Chemical conjugation of biomolecules and amide-to-triazole substitutions via copper (I) catalyzed 
alkyne azide 1,3-dipolar cycloadditions (CuAACs) were shown to have the potential for improvement 
in medical applications such as, but not limited to, tumor-targeting/tumor-detecting ability as well as 
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the potential for improved drug stability and efficacy. These limitless capacities of CuAAC result from  
the selectivity of the reaction, ease to perform, and various choice of medium. To further exploit this 
reaction, detailed investigation into CuAAC transition states should be carried out to determine the 
‘true’ reaction mechanism and therefore achieve better control of the reaction itself. Although CuAAC 
was shown to be a very robust reaction and is widely used in peptide chemistry, its application in 
protein chemistry is therefore possible. There are many opportunities for the expansion of CuAAC into 
the field of protein modification and beyond. 
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Polymer–peptide hybrids as a highly immunogenic 
single-dose nanovaccine
Group A Streptococcus (Streptococcus pyogenes or 
GAS) is a Gram-positive extracellular pathogen, 
which not only causes pharyngitis (mild throat 
infection) and pneumonia (lung infection), but 
also life-threatening toxic shock syndrome and 
autoimmune postinfectious diseases, including 
acute glomerulonephritis, rheumatic fever and 
rheumatic heart disease [1,2]. Rheumatic fever 
is the most common acquired heart disease 
in children worldwide and, if left untreated, 
leads to the development of rheumatic heart 
disease, which causes 1.4 million deaths per 
year [3]. GAS is among the top ten most deadly 
pathogens in the world, and causes extensive 
health problems, especially in developing 
countries and in indigenous populations in 
developed countries. It has been reported that 
Aboriginal communities in Australia suffer 
the highest incidence of rheumatic fever and 
rheumatic heart disease worldwide [2]. 
The most effective and economically feasible 
way to combat GAS-associated diseases is the 
vaccination of population groups at risk [4]. 
Presently, the required vaccine does not exist 
on the market. Protection against GAS infection 
has been correlated with host production of 
opsonic antibodies against the major virulent 
factor of GAS, the M protein. However, trials to 
develop a vaccine against this pathogen based on 
whole organisms or M protein were unsuccessful 
because they stimulated the production of 
autoreactive T and B cells by the human 
immune system [5,6]. Thus, the use of a peptide-
based subunit vaccine is the only practical 
approach that can lead to the development of 
a safe prophylactic vaccine against GAS disease 
and postinfection complications [7–9]. 
Peptide-based subunit vaccines are designed to 
possess only the minimal microbial components 
(i. e., peptide epitope) required to stimulate the 
desired immune response [10]. These vaccines 
are usually chemically synthesized, thus not 
infectious, chemically and physically more 
stable, and are typically easier and cheaper to 
produce than classical vaccines. The use of 
minimal pathogen components greatly reduces 
the risk of autoimmune and allergic responses [6]. 
However, as the microbial component is reduced 
to minimum, peptide-based vaccines require 
the help of an adjuvant (immunomodulators or 
immune potentiators) to produce the desired 
immune responses. In most cases, even with the 
help of an adjuvant, a single dose of peptide-
based vaccine is insufficient to elicit a significant 
immune response [11,12]. 
Only a limited number of adjuvants have been 
approved for human use. The major problem 
associated with the use of these stimulatory 
components of the vaccine is their toxicity 
and potential for delayed reactogenicity  [13]. 
Aim: To explore four-arm star poly(t-butyl)acrylate (PtBA)–peptide and linear PtBA–peptide conjugates as 
a vaccine-delivery system against Group A Streptococcus. Materials & methods: PtBA nanoparticles bearing 
J14 peptide epitopes were prepared via alkyne-azide 1,3-dipolar cycloaddition ‘click’ reaction. The 
conjugated products were self-assembled into small or large nanoparticles. These nanoparticle vaccine 
candidates were evaluated in vivo and J14-specific antibody titers were assessed. Results & discussion: Mice 
vaccinated with the nanoparticles were able to produce J14-specific IgG antibodies without the use of an 
external adjuvant after a single immunization. We have demonstrated for the first time that the immune 
responses against self-assembled PtBA nanoparticles are stronger for the smaller sized (~20 nm) nanoparticles 
compared with the larger (~500nm) PtBA nanoparticles. Conclusion: PtBA analogs have the potential to 
be developed as potent carrier systems for single-dose synthetic vaccines. 
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were able to induce significant amounts of IgG1, 
IgG2b and IgG3 isotypes [25]. 
Herein, we report the development of 
nanoparticle vaccine candidates against GAS 
based on the J14 chimeric peptide conjugated 
to two different carrier systems: a four-arm 
star poly(t-butyl)acrylate (PtBA) polymer and a 
linear PtBA polymer. The constructs were self-
assembled to form nanoparticles with different 
sizes prior to immunological evaluation. The 
immunogenicity was evaluated in a B10.Br 
(H-2K) mouse strain after single immunization. 
We demonstrated that immune responses against 
the self-adjuvanting, self-assembled chimeric 
PtBA-peptide nanovaccines were size dependent. 
Materials & methods
n Preparation of azide-end J14 
peptide (N3J14) & polymer molecules
N3J14 peptide was synthesized via fluorenyl-
methyloxycarbony-based solid-phase peptide 
synthesis as previously described [27]. Synthesis 
of azidoacetic acid and the PtBA polymer 
carriers are reported in the SUPPLEMENTARY MATERIALS 
(see online at www.futuremedicine.com/doi/
suppl/10.2217/NNM.13.7).
n Preparation of polymer–peptide 
conjugates & self-assembly into 
nanoparticles
The four-arm star PtBA polymer (d)-peptide 
conjugate and linear PtBA polymer (l)-peptide 
conjugate were synthesized via 1,3-dipolar 
copper catalyzed alkyne-azide cycloaddition 
(CuAAC) or ‘click’ reaction in a similar manner 
to that which has been previously described 
(FIGURE 1; for reaction details see SUPPLEMENTARY 
MATERIALS) [25]. 
Self-assembly of four-arm star PtBA-J14 
(D-J14) into particles
The resulting d-J14 product (in N,N-dimethyl-
formamide [DMF]) was filtered through a 
0.45-µm hydrophobic polytetrafluoroethylene 
filter. The nanoparticles were formed via a self-
assembly process in a water/DMF mixture. Endo-
toxin-free water (2.33 ml) was added dropwise to 
the filtered, stirred DMF solution for 1.5 h at a 
rate of 0.025 ml/min. The nanoparticles formed 
were later dialyzed for 2 days against Millipore 
Simplicity® UV water (Millipore, Queensland, 
Australia) using a presoaked and rinsed dialysis 
bag (MWCO 3500, Thermo Scientific Snake-
skin® Pleated Dialysis Tube; Thermo Scientific, 
Victoria, Australia) to remove remaining peptide 
and residual copper and DMF. The excess water 
Therefore, the use of a delivery system that 
does not require an external microbial-based 
adjuvant is favorable. Several strategies have 
been examined to deliver peptide epitopes [7,9,14]. 
One such strategy is to form a nanosized delivery 
system. Some of the advantages of developing 
nanosized particles are: the peptide immunogens 
incorporated into nanoparticles are presented 
to the immune system more effectively; the 
nanoparticles are more stable against enzymatic 
degradation; and the nanoparticles can often 
be delivered without an external adjuvant. The 
nanotechnological approach to produce subunit 
vaccines is considered to be one of the most 
advantageous [15–19]. 
The major virulence factor contributing to the 
pathogenicity of GAS is the coiled-coil a-helical 
M protein, which is located on the outer 
membrane of Streptococcus species. Epitopes 
derived from the highly variable N-terminal 
peptide sequence of the M protein were reported 
to induce strong protective responses; however, 
these vaccine candidates were GAS strain specific 
[20]. More than 200 different GAS strains have 
been identified, and thus the development of an 
anti-GAS vaccine via this approach is impractical 
[11,21]. On the other hand, immunization with 
the p145 peptide derived from the conserved 
C-terminal region of the M protein also resulted 
in protective responses. However, further 
studies of the p145 sequence by bioinformatics 
analysis indicated that antibodies directed 
against p145 are able to crossreact with human 
tissues [22,23]. Therefore, a chimeric peptide, 
J14 (KQAEDKVK[ASREAKKQVEKALE]
QLEDKVK) was designed that contains the 
minimal protective epitope (in square brackets) 
enclosed within the yeast helical ‘promoting’ 
sequence (CGN4). This epitope was able to 
elicit protective antibodies against the parent 
peptide, p145, without stimulating crossreactive 
responses [24]. 
Recently, we demonstrated the use of an 
amphiphilic polymer–peptide hybrid as a 
useful delivery system for peptide-based subunit 
vaccines [25]. Consisting of a hydrophobic 
polymer and a hydrophilic peptide conjugated 
head to tail, the hybrid was able to self-assemble 
into small nanoparticles (21 nm). We verified 
the presence of the peptide on the surface of the 
nanoparticles via immunogold labeling. Further 
experimentation showed that vaccinated B10.Br 
(H-2K) mice produced high titers of the peptide-
specific IgG antibodies after three vaccinations 
via subcutaneous or intranasal routes [25,26]. We 
previously identified that d-J14 nanoparticles 
www.futuremedicine.com 37future science group
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(resulting from dialysis) was evaporated to yield a 
1 mg/ml solution. The diameter of the nanopar-
ticles produced was small (19 nm) when analyzed 
using dynamic light scattering technique (DLS) 
(SUPPLEMENTARY FIGURE 2). 
Self-assembly of linear PtBA-J14 (L-J14) 
into particles
Following the conjugation reaction, the resul-
tant l-J14 in DMF was filtered using a 0.45-µm 
hydrophobic polytetrafluoroethylene filter. The 
self-assembly process was initiated by dropwise 
injection of 2.33 ml of Millipore water into the 
filtered 1 ml of DMF over 1.5 h at 0.025 ml/min 
while stirring. The mixture was then dialyzed 
against Millipore water for 2 days. The final con-
centration of l-J14 was found to be 1.0 mg/ml. 
DLS analysis of l-J14 found the particle diameter 
to be 530 nm (SUPPLEMENTARY FIGURE 3). 
n Immunological evaluation of vaccine 
candidates
Subcutaneous immunization
A total of 40 female B10.Br (H-2K) mice 
(5–7 weeks old; Animal Resource Centre, Perth, 
Australia) were used for the immunization trial. 
Mice (n = 5 per group) were injected subcuta-
neously at the tail base on day 0 with a total 
of 50 µg of immunogen (equal to 35 µg of J14 
peptide) in sterile-filtered phosphate-buffered 
saline (PBS). Immunogens consisted of: d dis-
solved in DMF and dialyzed against Millipore 
water for 2 days and then physically mixed with 
J14 (d plus J14); particle formulation of d-J14; 
and particle formulation of l-J14. One positive 
control group received 37.5 µg of J14 emulsified 
in a total volume of 50 µl of complete Freund’s 
adjuvant (CFA)-PBS (1:1). Three negative con-
trol groups were administered with 50 µl of 
PBS or 23.8 µg of d in 10% DMSO in PBS, or 
23.8 µg of l in 10% DMSO in PBS. DMSO was 
previously shown not to be immunogenic [28]. 
These doses were based on the content of pep-
tide and polymers in polymer–peptide hybrid, as 
previously described [25]. 
Vaccine candidates were delivered sub-
cutaneously as this route of administration is 
routinely used during the early stages of vac-
cine development. Furthermore, J14 peptides 
have previously been delivered via the same 
route [11,20]. The initial study on d-J14 was also 
performed via subcutaneous administration [25]. 
Collection of serum
A total of 20 days after the single immuniza-
tion, serum was collected for the measurement 
of systemic antibodies. Blood was collected from 
mice via the tail artery and allowed to clot for 
at least 30 min at 37°C. Serum was collected 
after centrifugation for 10 min at 3500 rpm, and 
stored at -20°C. 
Determination of IgG antibody titers 
by ELISA
An ELISA was used to measure J14-specific 
murine serum IgG, as described elsewhere [29]. 
Tested compounds were compared with the 
positive control J14 plus CFA, as well as with 
the PBS-only negative control group. The titer 
was described as the lowest dilution that gave 
an absorbance of >3 standard deviations above 
the mean absorbance of the control wells (blank 
wells coated with J14 only). 
Statistical analysis
Statistical analysis of antibody titers between 
groups was performed using a one-way analysis 
of variance followed by the Tukey’s post hoc test 
[11]. GraphPad Prism® 5.00 software (Graph-
Pad Software, Inc., CA, USA) was used for sta-
tistical analysis, with p < 0.05 considered to be 
statistically significant. 
Results
n Characterization of D-J14 & L-J14 
particles
d-J14 and l-J14 were synthesized via CuAAC 
between the polymers (d and l) and the N3J14 
peptide. The conjugation between the PtBA 
cores and the J14 peptide were analyzed, and 
peptide substitution was confirmed using ele-
mental microanalysis. A significant increase 
in the nitrogen-to-carbon (NC) ratio before 
(polymer cores alone) and after (PtBA with J14 
peptide) conjugation was observed. An NC 
ratio of 0.13 was recorded for l-J14 compared 
with 0.01 for l alone, indicating that one (0. 86 
peptide epitope on average) peptide epitope was 
conjugated per PtBA37-(≡)2 core. On the other 
hand, analysis of the d-J14 conjugates showed 
an average NC ratio of 0.15 compared with that 
of d (NC = 0.02), indicating an average of five 
(4.65 peptide epitope on average) peptide epitope 
attachments per PtBA37-(≡)8 core. 
Following self-assembly (micellization), 
size analysis of the nanoparticles using DLS 
revealed that l-J14 particle diameter was found 
to be 530 nm (TABLE 1). Dendrimer d-J14 formed 
nanoparticles 19 nm in diameter. Transmission 
electron microscopy analysis of the nanoparticles 
illustrated good size correlation with the DLS 
results (FIGURE 2). 
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Figure 2. Transmission electron microscope 
image of D-J14. Particles approximately 20 nm 
in size were observed. 
Table 1. Particle diameter and zeta-potential of D-J14 and L-J14 measured in water 
by dynamic light scattering technique. 
Particle Size (nm) Zeta-potential (mV)
D-J14 19 ± 2 29 ± 4
L-J14 530 ± 100 21 ± 5
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The surface charge of the nanoparticles, 
as measured by zeta-potential, changed from 
33 mV for the free J14 epitope to 29 mV for the 
d-J14 nanoparticles and to 5.39 mV for the l-J14 
nanoparticles. Analyses of the results suggested 
that d-J14 nanoparticles are rather stable parti-
cles, while l-J14 may aggregate due to the small 
potential value [30]. 
The stability of the self-assembled nano particles 
was tested by the use of different methods: dilu-
tion in water, sonication, ‘remicellization’ once 
lyophilized, and a storage temperature-stability 
study. Solvent dilution (up to a dilution factor of 
16) and sonication (under 5 min) did not lead to 
immediate nanoparticle size alterations. Remi-
cellization of lyophilized d-J14 only resulted in 
the formation of large nanoparticles, illustrating 
the disadvantage of storing the nanoparticles as a 
dry powder. Once stored at -20°C overnight, the 
nanoparticles aggregated to form microparticles. 
The peptide epitope was designed to mimic 
the helical conformation of GAS M protein. 
Circular dichroism analysis was performed to 
investigate the structure of J14 when conjugated 
to the polymers. It was found that the J14 pep-
tide adapts the a-helix secondary structure upon 
conjugation to the d and l polymers, similar to 
previously reported findings [25]. 
Immunogenicity of nanovaccines
In our preliminary studies, it was observed that 
21-nm PtBA37-(J14)8 nanoparticles generated 
significant J14-specific IgG antibody produc-
tion against the J14 peptide in a murine model 
on day 58 after three immunizations [25]. In this 
study, J14-specific IgG antibody production was 
determined using ELISA on day 20 after a single 
immunization (FIGURE 3). 
The J14-specific IgG antibody titers gener-
ated against d-J14 were statistically similar to the 
positive control CFA plus J14 emulsion. However, 
l-J14 produced a greater than tenfold lower IgG 
antibody response. No J14-specific IgG antibod-
ies were produced for any of the other groups 
(PBS, d or l). It was also observed that admixed 
J14 and polymer(s) showed no J14-specific IgG 
response. 
Endotoxin quantification was also investi-
gated. The endotoxin level of the nanoparticles 
was less than the endotoxin limit concentration 
of 1.5 IU/ml, signifying that the high antibody 
titer after primary immunization was not due to 
endotoxin contamination. 
Discussion
n Method development
An optimal vaccine-delivery system is able to 
maximize the immune response against desired 
antigens without inducing any adverse effects. 
One of the most successful approaches to pro-
duce such a delivery system is to utilize the abil-
ity of nanoparticles, composed of nontoxic mate-
rials, to mimic pathogenic infection [15,31–33]. 
With this aim, we utilized two different acry-
late polymer analogs as the delivery platform: 
(four-arm star PtBA [d] and a linear PtBA [l]), 
with J14 peptide epitope as the antigenic com-
ponent (FIGURE 1). The amphiphilic architecture 
of the vaccine’s final constructs consisted of a 
hydrophobic polymeric (PtBA) core and hydro-
philic J14 peptides. With similar features, the 
amphiphilic structures were usually able to form 
micelle-like constructs in water [34]. To maximize 
the presence of the peptide epitope on the surface 
of the micelle, the polymer was conjugated to 
triprop-2-ynylamine, resulting in eight and two 
alkyne functional groups for the four-arm star 
PtBA and linear PtBA, respectively. These alkyne 
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functional groups enabled conjugation of the J14 
epitope to the polymers. 
The f inal vaccine candidates, d-J14 and 
l-J14, were synthesized via CuAAC ‘click’ 
reaction. In this reaction, the terminal alkyne 
groups from the polymers reacted selectively 
to the azide moiety from the peptides to give 
1,4-disubstituted 1,2,3-triazole derivatives 
(FIGURE 1) [35]. This conjugation reaction was 
chosen not only because of its ability to join 
two large subunits together under simple reac-
tion conditions, but also because the reaction 
produced the target product in high yield and 
purity [25,36,37]. 
The CuAAC reaction requires the presence 
of copper to catalyze the ‘click’ reaction [38]. In 
this work, we used copper wire (Cu0). There 
are several advantages of the use of copper wire: 
the presence of an excess copper repository; easy 
removal of copper wire upon completion of the 
reaction; and the possibility of reusing the cop-
per wire for the next reaction (cost effective) 
[25,39]. The chemistry behind the use of copper 
wire has been established. It was reported that 
a chemical equilibrium exists between Cu0, 
Cu+ and Cu2+ [40]. The Cu0 and Cu2+ ions were 
able to comproportionate to produce the Cu+ 
ion, the catalytic agent needed for the CuAAC 
reaction [38,40]. 
n Nanoparticles as vaccines
There are several reviews summarizing the rela-
tionship between the type of particulate adju-
vant, its size, and the resultant immune response 
[16,31,33]. Surprisingly, there have been no stud-
ies on the influence of the size of polyacrylate-
based immunogens on immune responses, even 
though the safety profile of polyacrylates is well 
established and analogs of polyacrylates have 
been used since the 1960s for pharmaceuti-
cal purposes [41–43]. In this study, we report 
on the influence of size on the hybrid PtBA 
polymer–peptide nanoparticles for prompt-
ing antigen-specific antibody production in a 
murine model. 
Single-dose vaccine injection is not a typical 
vaccination methodology for synthetic com-
pounds because they lack the ‘danger signal’. 
Thus, to trigger the appropriate immune activa-
tion cascades, multiple doses of synthetic vaccine 
are often required with additional strong adju-
vants [11,44]. However, during the immunologi-
cal evaluation of the nanoparticles, we observed 
a very strong immune response after a single 
immunization. High titers of IgG antibody pro-
duction for the d-J14 vaccine candidate were 
observed and were comparable with an emulsion 
of J14 with the gold-standard adjuvant, CFA. 
By contrast, the larger nanoparticles, l-J14, pro-
duced lower antibody titers. It was reported that, 
in contrast to larger particles (100 nm), small 
nanoparticles (25 nm) were easily transported 
into lymphatic nodes to activate dendritic cells 
[45]. Similarly, the high immunogenicity of d-J14 
nanoparticles is suggested to be related to its 
ability to reach lymph nodes much more effi-
ciently than l-J14. By contrast, it was reported 
that only 10% of larger nanoparticles (>100 nm) 
were able to be transported in a similar manner, 
therefore resulting in the low antibody titers [45]. 
CFA is known to be very toxic and cause seri-
ous local inflammation [46,47]. It was reported 
that the inflammatory reaction can be due to 
the influx of leukocytes and as a result of gran-
ulomatous reactions at the injection spot [47]. 
A few days after the CFA plus J14 injection, 
we observed white postinjection spots (possi-
bly necrosis) in all five mice (data not shown). 
However, both nanoparticles (d-J14 and l-J14) 
did not induce any visible sign of inflamma-
tion around the local injection area. This sug-
gests lower toxicity of the vaccine candidates. In 
addition, it was reported that acrylic polymers 
have potentially low cytotoxicity [48], thus sub-
stantiating our observation with regard to d-J14 
and l-J14. 
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Figure 3. J14-specific IgG antibody titers 20 days after single subcutaneous 
immunization of individual mice. Mean specific IgG antibody titers are 
represented as a bar. Statistical analysis was performed using one-way analysis of 
variance followed by Tukey’s post hoc test. 
***p < 0.001.  
CFA: Complete Freund’s adjuvant; ns: Not significant (p > 0.05); 
PBS: Phosphate-buffered saline.
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Polymers have been used for vaccine delivery 
for many years. Polymeric nanoparticles were 
produced as stable beads with desired size and 
then the peptide antigens were attached to their 
surface [16]. By contrast, in this study the poly-
mer was initially conjugated to peptide and the 
product was self-assembled to form nanopar-
ticles. In addition, we demonstrated for the 
first time that self-assembled nanoparticles with 
20-nm size were able to induce strong immune 
responses in mice after multiple immunizations 
[25]. We have shown that smaller self-assembled 
polyacrylate-based nanoparticles (20 nm) were 
indeed more immunogenic than bigger particles 
(500 nm). By contrast, Reddy et al. showed that 
25-nm polymer-bead nanoparticles were signifi-
cantly more immunogenic than 100-nm ones 
[45]. Thus we have shown that self-assembled 
nanoparticles  demonstrated similar behavior 
to the polymeric beads as self-adjuvanting moi-
eties. Furthermore, we found that d-J14 and 
l-J14 tend to form particles with a specific size, 
and our efforts to produce different sizes for the 
same compound were unsuccessful. Finally, we 
demonstrated strong immune responses after 
a single injection. This finding broadens the 
opportunity for these self-assembled particles to 
be used as a vaccine-delivery platform; for exam-
ple, for therapeutic cancer vaccines where quick 
and strong immune response is required [49,50]. 
Conclusion & future perspective
Linear PtBA and dendritic four-arm star PtBA 
polymers conjugated to the minimal chimeric 
J14 epitope derived from GAS M proteins were 
shown to elicit a strong J14-specif ic IgG 
antibody response on day 20 after a single 
immunization. 
We presented the relationship between the 
size of the self-assembled vaccine and the subse-
quent antibody production. Analysis of ELISA 
results highlighted five main findings:
 20-nm PtBA-(J14)8 nanovaccines (d-J14) 
were able to induce high titers of J14-specific 
IgG antibody production, comparable with 
the gold standard adjuvant, CFA, with a J14 
peptide emulsion after single immunization;
 Low but significant IgG antibody production 
was observed for both near-micron-sized 
l-J14 particles compared with the negative 
control PBS;
 Conjugation of the J14 epitope to the respec-
tive delivery systems (d and l) was crucial for 
the production of J14-specific antibodies;
 All candidates were able to induce antibody 
production in mice without the use of an 
additional adjuvant. 
We demonstrated the advantages of the small 
(~20 nm) PtBA nanoparticles as a very promis-
ing delivery platform for therapeutic vaccine 
where strong and rapid immune responses are 
required (e. g., therapeutic vaccines). 
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Executive summary
Introduction
  Group A Streptococcus (GAS) causes postinfection complications that lead to more than 1.4 million annual deaths. 
  Vaccines against GAS utilizing the J14 epitope derived from GAS M protein were developed, characterized and tested in a murine 
model. 
Materials & methods
  The polymer–peptide hybrids were synthesized via copper catalyzed alkyne-azide 1,3-dipolar cycloaddition ‘click’ reaction. 
  Dendritic and linear poly(t-butyl)acrylate (PtBA)-J14 peptide hybrids were self-assembled in an aqueous solution to form small (19 nm) 
and large (530 nm) nanoparticles. 
Results & discussion
  Immunological studies in B10.Br mice showed that J14-specific IgG antibodies against Streptococcus pyogenes M protein were elicited 
by all three vaccine candidates after a single immunization without the use of an additional adjuvant. 
  Conjugation between the polymers and J14 peptide was a prerequisite for the induction of J14-specific antibodies.
  The smaller PtBA vaccine particulate induced significantly higher antibody titers than its larger counterparts. 
  The small dendritic PtBA nanovaccines induced IgG antibody titers comparable with the positive control (a J14 emulsion with the gold 
standard adjuvant, complete Freund’s adjuvant). 
  The strong immune responses were induced after single administration of the nanoparticles.
Conclusion & future perspective
  This is the first time that the size–antigenicity relationship of self-assembled, polymer-based nanovaccines has been reported. 
  Modification of PtBA repeat units and degree of branching are of interest for optimization purposes. This single immunization-based 
nanoparticulate antigen-delivery platform may be applied for the development of therapeutic vaccines. 
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Australia) or GL Biochem Ltd (Shanghai, China); diisopropylethylamine (DIPEA), 
trifluroacetic acid (TFA), diethyl ehter (EtOEt), dichloromethane (DCM) and 
piperidine were obtained from Merck (Darmstadt, Germany); triisopropylsilane (TIS), 
dimethylsulfoxide (DMSO), sodium azide (NaN3), and copper wire were purchased 
form Sigma-Aldrich (Castle Hill, NSW, Australia); and Millipore water equipment 
with endotoxin filter (18.2 MΩm) was obtained from New England Biolab (Arundel, 
QLD, Australia). Tert-butyl acrylate (tBA, 99% Aldrich) was passed through a basic 
alumina column (activityI) to remove inhibitor. CuBr (99.9%, Aldrich), CuBr2 
(99.9%, Aldrich), basic alumina (Aldrich: Brockmann I, standard grade, ~ 150 mesh, 
58 Å), triethylamine (TEA, 99%, Fluka), tripropargyl amine (TPA, 98%, Aldrich), 
tetrahydrofuran (THF, 99.8%, LAB-SCAN), MeOH (A.R. grade, Univar) were used 
as received. Pentaerythritol tetrakis(2- bromopropionate) (4BrPr) was used to prepare 
4-arm stars and was synthesized according to a published procedure [S1]. All other 
reagents were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). ESIMS 
were performed on a Perkin-Elmer-Sciex API3000 using the Analyst 1.4 (Applied 
Biosystems/MDS Sciex, Toronto, Canada) software. Samples (1-10 µL) were injected 
into ACN-H2O mobile phases containing 0.1% (v/v) acetic acid and run in positive 
ion mode. 1H NMR spectra were recorded on Bruker Avance 500 MHz spectrometer 
(Bruker Biospin, Germany) at 298 K. Analytical RP-HPLC was performed using 
Shimadzu instrumentation (Class Vp 6.12 software, SCL- 10AVp controller, SIL-10A 
auto injector, LC-10AT pump, LC-10AD pump, Waters 486 tuneable absorbance 
detector; Kyoto, Japan) using a 0-100% linear gradient of solvent B over 40 min with 
a 1 mL/min flow rate and detection at 214 nm. Solvent A consisted of 0.1% (v/v) 
aqueous TFA and solvent B consisted of 90% ACN/H2O + 0.1% TFA. Separation 
was achieved on a Vydac (Hesperia, CA) analytical C18 column. Preparative RP-
HPLC was performed on a Waters Delta 600 system in linear gradient mode using a 
10 mL/minute flow rate, with detection at 230 nm. Separations were performed on a 
Vydac C18 preparative column. CD spectra were measured on a JASCO (Tokyo, 
Japan) J-710 spectropolarimeter using quartz cuvette of 1 mm path length at 23 °C. 
 
Absolute Molecular Weight SEC: 
Absolute molecular weights of polymers were determined using a Polymer Labs 
GPC50 Plus equipped with dual angle laser light scattering detector, viscometer and 
differential refractive index detector. HPLC grade tetrahydrofuran was used as eluent 
at a flow rate of 1 mL/min. Separations were achieved using two PLGel Mixed C (7.8 
x 300 mm) SEC columns connected in series held at a constant temperature of 40 °C. 
The triple detection system was calibrated using a 2 mg/mL PSTY Standard (Mwt = 
110 K, dn/dc = 0.185 and IV = 0.4872 mL/g). 
 
Transmission electron microscopy: 
A sample of the construct was added to glow discharged carbon coated 200 mesh 
grids for 3 min and then wicked off with filter paper. Pictures were taken from a JEM-
1010 transmission electron microscope (JEOL Ltd., Japan) operated at 80 kV.  
 
Particle size and zeta potential: 
A Zetasizer Nano ZP instrument (Malvern Instruments, UK) with DTS software was 
used for particle size and zeta potential measurements of three vaccine candidates. 
Sizes were analysed using a non-invasive backscatter system and zeta potentials were 
measured using M3-PALS technique. Measurements were taken at 25 °C with 
scattering angle of 173° using disposable capillary cuvettes. The experiments were 
performed at least in triplicates.  
 
Circular dichroism spectroscopy 
Peptide confirmation (secondary structure) studies were carried out using a Jasco J-
710 Circular Dichroism spectrometer. The spectra were recorded from 260 nm to 190 
nm. The J14 peptide showed more random than α-helical conformation when tested in 
water. However, upon conjugation to the polymer and later when self-assembled in 
water, typical α-helical confirmation were observed for D-J14 (characteristics peaks 
(minimum) at 208 nm and 222 nm), similarly to those previously reported by 
Skwarczynski [S2, S3]).  
 
Synthesis of azidoacetic acid, N3CH2COOH.  
Azidoacetic acid was synthesized as previously described by Moutinho’s group [S4] 
with modifications. Sodium azide (NaN3, 1.27 g, 0.02 mol) was dissolved in cold 
milli-Q water (10 mL) and was stirred for five minutes at low temperature. 
Bromoacetic acid (BrCH2COOH, 1.37 g, 0.01 mol) was added and the reaction 
mixture and stirred overnight in an ice bath. Extraction was performed using diethyl 
ether (3 x 75 mL) upon pH adjustment to 2 using 5% hydrochloric acid (4.5 mL). The 
solvent was evaporated to obtain a colourless oil (0.436 g, 44%). 1H NMR (CDCl3): δ 
3.95 (s, 2H, N3CH2COOH), 10.3 (bs, 1H, R-COOH). 
 
Synthesis of azide-J14 peptide epitope, N3J14. 
Peptide was produced as previously described via Fmoc chemistry solid phase peptide 
synthesis (SPPS) [S3]. Peptide purity was verified by analytical RP-HPLC and ESI-
MS techniques. RP-HPLC analysis (C18 column): Rt = 19.7 min. ESI-MS, [M+2H]2+ 
m/z 1719.2 (calc 1719), [M+3H]3+ m/z 1146.7 (calc 1146.6), [M+4H]4+ m/z 860.2 
(calc 860.2), [M+5H]5+ m/z 688.5 (calc 688.4), [M+6H]6+ m/z 573.8 (calc 573.8); 
MW 3436.87. 
 
Synthesis of poly(t-butyl)acrylate (PtBA) polymer with 2-alkyne and 8-alkyne 
end-groups, PtBA37-(≡)2 (L) and PtBA37-(≡)8 (D). 
The polymers were synthesized via successive atomic-transfer radical polymerization 
(ATRP) followed by copper-catalyzed alkyne azide 1,3-dipolar cycloaddition 
(CuAAC) reaction. All analysis was performed as previously described [S2]. 
 
Synthesis of PtBA with 8-alkyne end-groups, PtBA37-(≡)8 (D).  
PtBA37-(≡)8 was synthesized as previously described [S2]. 1H NMR (CDCl3): δ 1.11 
(m, 12H, (=CH(CH3)4), 1.45 (b, =COOC(CH3)4), 1.82, 2.23 (b, (R-(CH(CH3)-
poly(CH2CH(COOtBu))-R’)4), 2.47 (m, 4H, (=CH(CH3)4), 3.48, (s, 16H, (-N(-CH2-
C≡CH)2)4), 3.88, (s, 8H, (triazole-CH2-N(CH2-R’)2)4), 3.94-4.22, (m, 8H, C(CH2-O-
R)4), 5.24, (m, 4H, ((R-CH2CH(COOtBu)-1,2,3-triazole ring)4) 7.72, (m, 4H, methine 
protons of 1,2,3-triazole ring). Mn = 19000; PDI = 1.09. 
 
Synthesis of PtBA polymer with azide end-group, PtBA37-N3.  
NaN3 (0.225 g, 3.46 x 10-3 mol) was added to a stirred solution of PtBA37-Br (1.50 g, 
3.0 x 10-4 mol) in 5 mL DMF. The reaction mixture was stirred for 24 h at R.T. The 
polymer was recovered by precipitation into methanol/water (50:50 v/v), filtered, 
then dried under high vacuum at 25 °C.  
 
Synthesis of PtBA polymer with dipropargyl end-group, P(t-BA37)-(≡)2 (L). 
In a 10 ml Schlenk tube, PtBA37-N3 (0.44 g, 8.8 x 10-5 mol), TPA (0.23 g, 1.76 x 10-3 
mol), and PMDETA (7.6 mg, 4.4 x 10-5 mol) were dissolved 2 ml toluene. The 
mixture was purged by Ar for 20 min and then CuBr (6.3 mg, 4.4 x 10-5 mol) was 
added under Ar atmosphere. The reaction was stirred for 1 h at R.T and the mixture 
was diluted by chloroform (10 ml). The solution was passed through a small Al2O3 
column to remove copper complex before being blown to dry and purified by 
preparative GPC. GPC: Mn = 5060, PDI = 1.09. 
1H NMR (CDCl3, Figure S1): d 1.11-1.23 (m, 9H, methyl groups of initiator), 1.43 (b, 
methyl protons of t-BA repeat units), 1.82, 2.21 (b, methylene and methine protons of 
polymer backbone), 2.40 (s, 1H, , (-NCH2-C≡CH)2), 3.44 (s, 4H, (-NCH2-C≡CH)2), 
3.85 (s, 2H, methylene protons close to triazole ring), 4.07 (m, 2H, methylene protons 
of initiator residual), 5.25 (m, 1H, methine proton of t-BA unit close to triazole ring), 
7.63 (m, 1H, proton of triazole ring). 
 
Synthesis of PtBA-(J14)2 (L-J14) and PtBA-(J14)8 (D-J14) via CuAAC reaction. 
The four-arm star polymer (D; 2.0 mg, 0.10 µmol) and J14 peptide (4.5 mg, 1.0 µmol) 
were dissolved in DMF (1 mL). Similarly, linear polymer (L; 2.1 mg, 0.43 µmol) and 
J14 peptide (3.8 mg, 0.86 µmol) were dissolved in DMF (1 mL). Copper wires (Cu0), 
treated with concentrated sulphuric acid (5 min) then washed with water, methanol 
and dried under reduced pressure, were added to the solution. The reaction mixture 
was stirred between 5 to 7 hours at 50 °C in a temperature controlled oil bath. The 
wires were filtered off from the warm solution and washed with 1 mL DMF. The 
solutions were filtered using 0.45 µm hydrophobic PTFE filter before self-assembly 
process in aqueous solution. 
During the CuAAC reaction, we encountered a major difficulty in estimating 
the end point of the reaction. Due to the inability to use high performance liquid 
chromatography (HPLC) to observe the progress of the reaction, the only noticeable 
observation during the reaction was change of colour of the DMF solution, where at 
the end of the reaction, a light blue-green coloured solution was observed. Model 
CuAAC reaction performed in a similar manner suggested reaction completion within 
5 hours [S3]. Prolonged reaction (≥ 24 hours) resulted in a dark blue solution. This 
‘dark’ solution usually produced aggregated particles upon self-assembly in water. 
This aggregation might be caused by excessive oxidation of copper wire to form 
copper oxide (CuO), acting as massive nucleation sites. Another possibility is the 
presence of impurities, such as CuO, within the self-assembling solution, which may 
disturb micelle formation, resulting in disordered aggregation [S5].  
 
Limulus Amebocyte Lysate (LAL) Assay For Endotoxin Quantification.  
A chromogenic Limulus amebocyte lysate (LAL) endpoint assay (Pyrochrome; 
Associates of Cape Cod) was used to certify that endotoxin levels were below 
US/British pharmacopoeia limits. An endotoxin concentration limit of 1.5 IU/mL was 
set based on a minimal pyrogenic dose (K) of 0.075 IU/dose in 50 µL total volume 
(calculated using a 5 IU/kg limit for parenteral routes and a 15 g minimal mass for 5-7 
week old mice (JAXmice)). Assays were performed in polystyrene 96-well plates 
(with lids), using 50 µL total sample volumes. All consumables were certified 
endotoxin free. The following groups were assessed: 1) LAL reagent water (Lonza; 
negative control), 2) endotoxin standard curve, 3) polymer samples, and 4) positive 
polymer control (polymer spiked with endotoxin standard). A six-point standard curve 
(0.1-2 IU/mL), incorporating the endotoxin limit concentration (1.5 IU/mL), was 
constructed using control endotoxin standards (50 IU/mL; Associates of Cape Cod) 
diluted in LAL reagent water. Polymer samples were tested to ensure their pH was 6-
8 and that they do not absorb at 400-410 nm. Polymer samples (30 µL × 2/group) 
were diluted to 50 µL total volume with LAL reagent water (for quantifying 
endotoxin levels), or with LAL reagent water spiked with control standard endotoxin, 
to a final endotoxin level of 0.5 IU/mL (positive polymer control: ensures polymer 
samples do not affect the amount of endotoxin detected). Pyrochrome LAL reagent 
(50 µL/well), reconstituted with Glucashield buffer (Associates of Cape Cod; prevents 
(1,3)-β-D-glucan from activating the LAL cascade), was added to each sample, and 
the reaction incubated at 37 °C until all standard curve samples were yellow. 
Reactions were stopped with 50% (v/v) acetic acid-H2O (25 µL/well), and the optical 
density at 405 nm acquired using a SpectraMax 190 (Molecular Devices) microplate 
reader. Endotoxin levels were determined by comparison with the standard curve. 
 
 
Enzyme Linked Immunosorbent Assay (ELISA) Protocol For Antibody Titre 
Determination 
Reagents preparation 
1. Carbonate coating buffer (CCB) 
Sodium carbonate (Na2CO3, 1.93 g) and sodium hydrogen carbonate 
(NaHCO3,  
3.81 g) were dissolved in distilled water to make a one litre solution. The 
solution’s pH was adjusted to 9.6 with the addition of 3M HCl or 3M NaOH 
solutions. 
2. 5% w/v skim milk solution 
50 g of skim milk powder was weighted and dissolved in phosphate buffer 
saline (PBS) to make a one litre solution. Tween 20 (0.5 mL) was added to the 
solution and mixed. 100 mL of the 5% skim milk solution was diluted with 
900 mL of distilled water to make a one litre 0.5 % w/v skim milk solution. 
3. Wash buffer 
A one litre PBS solution was prepared using sodium chloride (NaCl, 8.5 g), 
sodium hydrogen phosphate (Na2HPO4, 1.48 g) and potassium dihydrogen 
carbonate (KH2PO4, 0.43 g), dissolved in one litre distilled water. The pH of 
the solution was adjusted to 6.8 with the addition of 3M HCl or 3M NaOH 
solutions. To the PBS solution, 0.5 mL of Tween 20 was added and mixed. 
 
ELISA protocol 
A 5 µL of antigen solution (J14, 10 mg/mL) was diluted in 10 mL of CCB. The 
resulting solution was used to coat a 96-well ELISA plate (100 µL/well) and was left 
overnight at 4 oC. Next, 5% skim milk was transferred (150 µL/well) and incubated at 
4 oC overnight to ‘block’ the plate, avoiding any non-specific antibody binding to the 
plate during analysis. Afterwards, the plate was washed twice with wash buffer 
followed by one time distilled water. Murine sera was added starting at 1/100 dilution 
in 0.5% skim milk. A serial dilution was then performed at 2-fold dilution factor. The 
ELISA plate was then incubated for 90 minutes at 37 oC. Upon incubation, the plate 
was washed with four times wash buffer and two times distilled water. Optical 
density (OD) of each plate was read at 450 nm following the addition of goat anti-
mouse IgG conjugated to horseradish peroxidase and ‘dark’ incubation for 20 
minutes. The antibody titer was determined based on the lowest dilution factor with 
an OD of more than the mean of control well’s OD plus 3 standard deviations.  
 
Illustrations and Tables 
 
Figure S1. 1H NMR chemical shift spectrum of PtBA-(≡)2 (L).  
 
 Figure S2. Dynamic light scattering analysis of D-J14 (multiple measurements). 
 
 Figure S3. Dynamic light scattering analysis of L-J14 (multiple measurements). 
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4.1 Introduction to this publication 
This chapter was submitted to Nanomedicine: Nanotechnology, Biology and Medicine as 
an original article. In this manuscript, the design of peptide epitopes via computational 
approaches, the synthesis of peptides and their lipopeptide (LCP) vaccine counterparts, 
and antibody production experiments were investigated. The lead vaccine candidate was 
able to produce high level of IgG antibodies, specific to parent (target) protein, without the 
use of additional adjuvant.  
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!Graphical Abstract: 
 
The development of subunit peptide-based vaccine against hookworm based on aspartic protease,  
Na-APR-1. The B-cell epitope (A291Y) was conjugated to lipid core peptide (LCP) via stepwise SPPS 
(i) and CuAAC reaction (ii). The products were able to self-assemble (iii) in PBS to form 
nanoparticles. 
 
Abstract: 
Necator americanus (hookworm) infects over half a billion people worldwide. Commonly, 
anthelminthic drugs are used to treat the infection, however, vaccination is also considered a viable 
disease control strategy. Thus, we have designed new B-cell peptide epitopes based on aspartic 
protease of N. americanus (Na-APR-1). The peptides were conjugated to self-adjuvanting lipid core 
peptide (LCP) systems via stepwise solid phase peptide synthesis (SPPS) and copper catalyst azide-
alkyne cycloaddition (CuAAC) reactions. The LCP vaccine candidates were able to self-assemble into 
nanoparticles, were administered to mice without the use of additional adjuvant and generated 
antibodies that recognized the parent epitope. However, only one LCP derivative was able to produce 
high titre of antibodies specific to Na-APR-1 and CD analyses of this compound unexpectedly 
showed a β sheet conformation for the incorporated epitope. This study provides important insight in 
epitope and delivery system design for the development of a vaccine against hookworm infection. 
 
!Keywords: Nanoparticles; Subunit peptide-based vaccine; lipid core peptide; epitope modification; 
hookworm parasite, peptide modification. 
  
!Background 
The hookworm Necator americanus infects over 500 million people worldwide (more than 
HIV/AIDS and malaria combined), predominantly in impoverished rural and tropical regions, causing 
one of the world’s most debilitating neglected tropical diseases (NTDs).1 Hookworm is possibly the 
most prevalent NTD in Oceania, infecting 5.5 million people, including Papua New Guinean and 
Aboriginal populations.2 Chronic hookworm infection results in long-term pathological consequences 
primarily due to ongoing intestinal blood loss caused by the feeding activities of these 
haematophagous parasites. This results in iron-deficiency anaemia and subsequent impaired physical 
and intellectual development in children, and has significant consequences on future economic 
productivity.3 
Hookworm infection can be treated effectively with chemotherapy. Cure rates after single-dose drug 
treatments can reach 72% but rapid reinfection necessitates regular drug administration to the entire 
population.4 This degree of drug failure, coupled with the widespread distribution of the disease and 
the potential emergence of drug resistance5 suggests that additional control measures are urgently 
needed.3,6 Indeed, development of a vaccine that would prevent acquisition of moderate or heavy 
intensity hookworm infections would be a major advance in reducing the morbidity caused by this 
parasite. 
Na-APR-1 is a cathepsin D aspartic protease expressed in the gut of adult N. americanus where it is 
responsible for initiating the haemoglobin digestive cascade, a process that degrades haemoglobin into 
small peptides to serve as nourishment for the parasite, an obligate blood-feeder. This molecule is an 
efficacious hookworm vaccine candidate, inducing high levels of antibody that bind to the gut of the 
parasite and neutralize the enzymatic activity of the protease, starving the worm and resulting in 
significantly diminished parasite burdens and blood loss in dogs following vaccination and challenge 
infection.7,8 
While Na-APR-1 shows promise as a hookworm vaccine antigen, scale-up production of the antigen 
has proven challenging and the yield of protein obtained from eukaryotic expression hosts is sub-
!optimal. Using epitope mapping approaches, we identified an immunogenic epitope of Na-APR-1 
(A291Y, p1, Figure 1A) that induces neutralizing antibodies which inhibit the ability of Na-APR-1 to 
cleave synthetic and natural substrates.9 We therefore hypothesized that antibodies to A291Y are 
protective and propose that, creating a subunit peptide-based vaccine against A291Y might be a viable 
strategy to control hookworm disease. 
Peptides are usually non immunogenic on their own and therefore require the addition of adjuvants to 
engender appropriate immune responses. We have previously shown the self-adjuvanting lipid core 
peptide (LCP) system to be an effective immune stimulant, inducing significant immune responses 
when conjugated to peptides derived from bacterial10,11 and parasite12,13 molecules. Another basic 
requirement for a peptide-based vaccine to induce the production of protective/neutralizing antibodies 
is to display peptide epitopes in a conformation that mimics the native protein. However, short 
peptides usually lose their native conformation, thus, modification of the epitope is essential to ensure 
generation of desired antibodies.11,13,14 In this paper, we report the development of a self-assembling, 
nanoparticulate, peptide-based vaccine against hookworm infection utilizing the A291Y epitope (and 
its derivatives) conjugated to the self-adjuvanting LCP system. 
With the aim to improve antibody production against Na-APR-1-based peptides, we devised a 
strategy to produce two additional peptides based on the p1 epitope, which were designed with the 
help of bioinformatics analyses. Based on the analysis of Na-APR-1 secondary structure, we 
constructed a chimeric epitope (p2) by flanking p1 with a yeast-derived coil promoting GCN4 protein 
sequence. Additionally, p3 peptide was designed based on the same region of Na-APR-1 protein 
(Figure 1A). Subsequently, p1, p2 and p3 peptides were incorporated into the LCP system by solid 
phase peptide synthesis (SPPS) and copper catalyses azide-alkyne cycloaddition (CuAAC) (Figure 
1). Constructs were self-assembled to form nanoparticles in PBS and subjected to immunological 
studies in BALB/c mice to identify the most antigenic peptides.  
 
 
!Methods 
Design of Epitopes 
The Na-APR-1 protein sequence was subjected to high accuracy homology and 3D structural 
modelling using CHPmodels 3.2 Server15 (template; PDB code 2PSG; software available at 
http://www.cbs.dtu.dk/services/CPHmodels/). The resulted 3D model was analysed using PyMOL 
Molecular Graphics System Version 1.5.0.4 (Schrödinger, LLC) then the secondary structure for the 
B-cell peptide epitope (p1) were extracted. Using the extended and chimeric approaches, modified 
peptides were then subjected to secondary prediction tools (Porter16 at http://distill.ucd.ie/porter/, 
PSIPRED17 at http://bioinf.cs.ucl.ac.uk/psipred/, GOR418 at http://npsa-pbil.ibcp.fr/cgi-
bin/npsa_automat.pl?page=npsa_gor4.html and Prof19 at http://www.aber.ac.uk/~phiwww/prof/) to 
further confirm the predicted the peptide secondary structure, in comparison to the epitope 
conformation within the protein. Amino acids were mutated in turn to a different residue and 
predicted to either maintain or improved the epitope helical conformation. The final aim was to 
produce the shortest modified epitope but having the closest predicted conformation to the protein 
sequence. 
Synthesis of Peptide Epitopes and LCPs 
Detailed procedure for peptides (p1, p2 and p3) and LCP (1, 2, 3, 4 and 5) syntheses are reported in 
the SUPPLEMENTARY MATERIALS.  
Particle Size Analysis by Transmission Electron Microscopy 
A peptide sample was dissolved in phosphate buffer saline (PBS) to a concentration of 1 mg/mL. 
Samples (10 µL) were put onto an ionized, 200-square-mesh carbon coated copper grid. After one 
minute, excess solution was dried out using filter paper. The processes were repeated twice. Grid was 
later inserted into electron microscope (JEM-1010, JOEL Ltd. Japan) for photo snaps. The 
microscope was operated at 100 kV. 
 
!Particle Size Analysis using Dynamic Light Scattering 
A sample was prepared in PBS at the same concentration as TEM (1 mg/mL). Solution was 
transferred to low volume disposable plastic cuvette and particle sizes were measured and analysed 
with Zetasizer software on Zetasizer Nano ZP instrument (Malvern Instrument, UK). Samples size 
measurements using M3-PALS technique at 25 oC with 173 o backscattering angle in triplicates. The 
average size by number was reported. 
Peptide Secondary Structure Studies using Spectropolarimetry 
Conformational studies were conducted using J-710 circular dichroism spectropolarimeter (Jasco 
Corporation, Japan). Peptides were dissolved in PBS at 1 mg/mL. Solution was transferred into a low 
volume 1.0 mm quartz cuvette. Peptide conformation studies were carried out at 260 nm to 190 nm 
wavelength range. Analysis was performed in triplicates and averaged. Spectra was normalized and 
reported as mean residual ellipticity (θ) versus wavelength. 
Intraperitoneal Immunization 
The James Cook University Animal Ethics Committee approved all protocols (A2004) and 
experiments were carried out in accordance with National Health and Medical Research Council 
(NHMRC) guidelines. Groups of five 5-8 week old female BALB/c mice (Animal Resource Centre, 
Perth, Australia) were intraperitoneally injected with 30 µg of samples in 100 µL of either 50 % (v/v) 
Freund’s adjuvant/PBS or 100 % PBS at day 0, 21, 33 and 45. Positive control groups received 
complete Freund’s adjuvant/PBS emulsion for the first immunization and incomplete Freund’s 
adjuvant/PBS mixtures were used for the subsequent administrations. The negative control group 
received 100 µL of PBS throughout the experiment. 
Serum collections 
Mice were euthanized on day 73 using CO2 gas and blood was collected via cardiac puncture. Sera 
were separated from blood using serum separation Z-Gel micro tubes (Sarstedt AG & Co, Nümbrecht, 
Germany) by spinning at 3000 rpm for 10 minutes and stored at -80 oC. 
!Determination of Immunoglobulin G (IgG) antibody titre by ELISA 
Antibody responses to the administered constructs were measured using indirect enzyme linked 
immunosorbent assay (ELISA) using a polycarbonate 96 well flat bottom plates (BD Bioscience, 
Maryland, USA). Peptide antigens (p1 or p3) were used to coat the plates at a concentration of 5 
µg/mL in 20 mM sodium carbonate buffer (pH 9.6), overnight at 4 oC. Unbound antigens were 
removed and plates were washed in endotoxin free Milipore® water for a minimum of three times. 
Non-reactive sites within wells were then blocked using 5 % skim milk in 0.05 % Tween 20/PBS and 
incubated at 37 oC for 1.5 hours. Plates were washed in a similar manner between incubations. 
Individual serum (1:100 to 1:12800 in blocking buffer) was added and plates were incubated at 37 oC 
for 1.5 hours. Primary IgG binding was detected using goat anti-mouse IgG-HRP (1:5000 in blocking 
buffer) at 37 oC for 1.5 hours. Secondary antibody binding was detected with ABTS reagent. Plates 
were read at 415 nm on a POLARstar Omega microplate reader (BMG Labtech, Victoria, Australia) 
and antibody endpoint titres determined by the lowest dilution factor that gave an absorption value of 
>3 times SD above the mean absorbance of their respective control wells. 
Statistical analysis 
Statistical analysis of antibody titres between groups was performed using a one-way analysis of 
variance (ANOVA) followed by the Tukey’s multiple comparisons test. GraphPad Prism® 6.0e 
software (Graph-Pad Software Inc., USA) was used for the statistical analysis. Differences were 
significant if p < 0.05. 
Antibody purification 
Sera from each group were pooled and IgG was purified by binding to protein G-sepharose 4B, 
overnight, at 4 oC incubation. Antibodies were eluted using 0.1 M of glycine buffer (pH 2.7) and the 
elute was neutralized using 1.0 M Tris buffer (pH 9). Purified antibodies were concentrated using 
Nanosep® centrifugal devices (molecular weight cut off < 10kDa) as per manufacturer’s 
recommendation and quantified using a NanoDrop 2000 UV-Vis spectrophotometer (Thermo 
Scientific, Australia) as previously described.7 
!Results 
Design of peptides (epitope) 
We have chosen a peptide derived from the hookworm protein Na-APR-1 (A291Y peptide, p1) for 
vaccine development. Firstly, the secondary structure of p1 within Na-APR-1 was determined using 
CHPmodels 3.2. Based on the server’s collections of protein data, calculations based on protein 
sequence secondary structure and water exposure predictions were performed. Porcine pepsinogen 
protein (PPP) was found to have the highest similarities to Na-APR-1 and was used as the template 
for Na-APR-1 protein modelling.15 Results showed that the p1 peptide within the protein adopted a 
mostly helical conformation with a short N-terminal fragment adopting a β-sheet secondary structure. 
This result was consistent with previously modelled Na-APR-1.7  
To ensure high reliability of prediction, additional APR-1 structural analyses were performed using 
the secondary structure prediction servers Porter+, PSIPRED, GOR4 and Prof (no protein homolog 
was used as template; each server utilized its specific calculation-based secondary structure 
prediction). Side-by-side comparison of the predictions corresponding to the p1 segment within Na-
APR-1 showed that it adopted a mainly α-helical conformation (SUPPLEMENTARY MATERIALS 
Figure S2). However, prediction of the conformation of the N-terminal fragment of the peptide was 
not consistent among the methods with 3 of the 5 prediction servers (CHPmodels 3.2, Porter+ and 
Prof) showing a short β sheet formation at the N-terminus of the peptide. Using this information, 
derivative peptide epitopes of p1 (p2 and p3) were designed. Data relating to the final conformational 
prediction for the epitopes are available in the Figure 2. 
Synthesis and Characterization of Peptide Epitopes and LCPs 
Peptides (p1, p2 and p3) and their LCP analogues (1, 2, and 3) were readily synthesized via Boc- or 
Fmoc-SPPS chemistry. Additionally, two LCPs (4 and 5) were synthesized via CuAAC reaction. 
LCPs (1-3) were easily obtained in their pure form upon HPLC purifications. Despite short peptides 
are relatively easy to purify, the presence of azide moiety within p1, p2 and p3 sequence resulted in 
slight difficulties during purification (azide was reported to be thermal sensitive20; also, we observed 
!impurities having relatively close molecular weight to the product). As such, pure fraction were 
collected and lyophilized on the same day to ensure the integrity of the purified azide-peptides. The 
compound library is illustrated in Figure 1. 
Peptide p1. Yield: 33 %. Molecular Weight: 1484.7. ESI-MS [M+1H+]1+ m/z 1485.2 (calc. 1485.7), 
[M+2H+]2+ m/z 743.4 (calc. 743.4). tR = 15.1 min (0 – 100 % Solvent B; C18 column), purity ≥ 95 %. 
Peptide p2. Yield: 30 %. Molecular Weight: 2325.7. ESI-MS [M+1H+]1+ m/z 2326 (calc. 2326.7), 
[M+2H+]2+ m/z 1163.5 (calc. 1163.9), [M+3H+]3+ m/z 775.9 (calc. 776.0). tR = 19.1 min (0 – 100 % 
Solvent B; C18 column), purity ≥ 96 %. 
Peptide p3. Yield: 32 %. Molecular Weight: 2382.8. ESI-MS [M+1H+]1+ m/z 2383.2 (calc. 2383.8), 
[M+2H+]2+ m/z 1192.3 (calc. 1192.4). tR = 21.9 min (0 – 100 % Solvent B; C18 column), purity ≥ 95 
%. 
LCP 1. Yield: 36 %. Molecular Weight: 3793.6. ESI-MS [M+2H+]2+ m/z 1897.6 (calc. 1897.8), 
[M+3H+]3+ m/z 1265.8 (calc. 1265.5), [M+4H+]4+ m/z 949.6 (calc. 949.4). tR = 36.8 min (0 – 100 % 
Solvent B; C4 column), purity ≥ 95 %. 
LCP 2. Yield: 30 %. Molecular Weight: 5359.5. ESI-MS [M+2H+]2+ m/z 2681.4 (calc. 2680.8), 
[M+3H+]3+ m/z 1787.9 (calc. 1787.5), [M+4H+]4+ m/z 1340.9 (calc. 1340.9), [M+5H+]5+ m/z 1073.2 
(calc. 1072.9), [M+6H+]6+ m/z 894.5 (calc. 894.3). tR = 34.0 min (0 – 100 % Solvent B; C4 column), 
purity ≥ 95 %. 
LCP 3. Yield: 35 %. Molecular Weight: 5475.6. ESI-MS [M+2H+]2+ m/z 2738.7 (calc. 2738.8), 
[M+3H+]3+ m/z 1826.5 (calc. 1826.2), [M+4H+]4+ m/z 1370.0 (calc. 1369.9), [M+5H+]5+ m/z 1096.1 
(calc. 1096.1), [M+6H+]6+ m/z 913.5 (calc. 913.6). tR = 38.4 min (0 – 100 % Solvent B; C4 column), 
purity ≥ 95 %. 
LCP 4. Yield: 59%. Molecular Weight: 10614.5. ESI-MS [M+7H+]7+ m/z 1517.3 (calc. 1517.4), 
[M+8H+]8+ m/z 1328.1 (calc. 1327.8), [M+9H+]9+ m/z 1180.7 (calc. 1180.4), [M+10H+]10+ m/z 1062.5 
!(calc. 1062.5). tR = 25.39 min (0 – 100 % Solvent B; C4 column), purity ≥ 95 %, copper content < 0.1 
ppm. 
LCP 5. Yield: 75%. Molecular Weight: 5579.6. ESI-MS [M+3H+]3+ m/z 1861.4 (calc. 1860.9), 
[M+4H+]4+ m/z 1395.8 (calc. 1395.9), [M+5H+]5+ m/z 1116.9 (calc. 1116.9), [M+6H+]6+ m/z 931.4 
(calc. 930.9), [M+7H+]7+ m/z 798.5 (calc. 798.1), [M+8H+]8+ m/z 698.7 (calc. 698.5). tR = 18.4 min  
(0 – 100 % Solvent B; C4 column), purity ≥ 95 %, copper content < 0.1 ppm. 
Peptides with amphiphilic properties can often self-assemble to form micro/nano structures in 
aqueous media.21 When dissolved in PBS, LCP compounds (1-5) were able to form particles. Size 
analyses were performed using photon correlation spectroscopy (or dynamic light scattering, DLS) 
and transmission electron microscopy (TEM) techniques. DLS results showed that all LCP 
compounds were able to self-assemble into nano-sized particulates in PBS (Table 1). TEM images of 
LCP compounds are shown (Figure 3) and size analyses correlated with the DLS results (Table 1). 
Circular dichroism (CD) analyses were performed on all peptides and LCP compounds to show that 
the peptides (p1, p2 and p3) adopted secondary structures (Figure 4). Unexpectedly, a more random 
than α-helical conformation was observed for all peptides, with negative bands at 205 nm, 207 nm and 
206 nm for p1, p2 and p3, respectively. LCP compound 1 also displayed a predominantly random 
conformation. LCP compound 2 showed some α-helical properties a strong minimum at 206 nm and a 
very shallow minimum at 222 nm while LCP compound 3 adopted a β-sheet conformation with a 
strong minimum at 213 nm. The two LCP compounds synthesized by CuAAC, 4 and 5, showed 
clearly α-helical conformation with two minima of 222/206 nm and 222/208 nm, respectively. As a 
reference, a highly disordered conformation (random coil) has a strong minimum at 197 nm and a 
weak positive at 217 nm; an α-helix has two strong minima at 222 nm and 208 nm, while a β-sheet 
exhibits a minimum at 217 nm.22 
Antibody generation and binding analyses 
Following the intraperitoneal administration of all peptides and LCP compounds, p1-specific IgG 
antibody titres were determined by probing p1 coated-ELISA plates with mouse sera (Figure 5A). 
!The levels of p1-specific IgG antibodies generated against all antigens were significantly higher than 
antibodies generated by negative control mice, who just received PBS. Antibody titres were not 
statistically different between mice immunized with CFA+peptides (p1-p3) and their LCP 
counterparts (1-5). LCP 2, synthesized via a stepwise approach, did not show any significant 
differences in generating p1-specific IgG compared to the CuAAC products (4 and 5). When p3-
specific IgG titres were similarly measured (using p3-coated ELISA plates) (Figure 5B), CFA + p3 
and LCP compound 3 showed the highest p3-specific IgG titres and the mean titre level was found to 
be significantly higher than those of other groups. Antibodies produced after immunization with p1 
and p2 or LCP compounds containing these antigens (1, 2, 4, and 5) showed lower specificity towards 
p3 compared to p1. Additionally, ELISA plates coated with Na-APR-1 were probed with pooled, 
purified IgG from each immunised group. A monoclonal antibody (mAb) against A291Y was used as a 
positive control.9 Results showed that antibodies that bound strongly to p3 (i.e. CFA + p3 and LCP 
compound 3) also bound to Na-APR-1. Importantly, antibodies produced upon immunization with the 
other compounds were not able to recognize Na-APR-1 (Figure 6).  
 
Discussion 
Most vaccines are designed primarily to induce humoral immunity, i.e. production of neutralizing or 
opsonizing antibodies. One of the most important properties of antibodies is their ability to recognize 
certain antigen conformations. For example, antigens with incorrect conformation might be able to 
bind to the major histocompatibility complex class II protein during antigen processing by antigen 
presenting cells (e.g. dendritic cells) but the antibodies generated against the antigen would not be 
able to recognize the parent protein (vaccine target), which has a different conformation. Thus, it is 
very crucial for a peptide-based vaccine to be conformationally ‘correct’ to ensure antibodies 
generated are able to bind to the desired target. Another desirable aspect of an antibody is 
immunogenicity. Peptides are non-immunogenic on their own and so the addition of an adjuvant (such 
as CFA) to a peptide or incorporation of a lipopeptide into a self-adjuvanting delivery system (such as 
!LCP) is usually required for immune stimulation.10,23 The LCP system is less toxic than CFA and has 
aided in inducing the desired secondary structure of incorporated peptide epitopes.11,12,24 
In attempts to analyse A291Y (p1) peptide conformation within the hookworm vaccine candidate, Na-
APR-1, we utilized a de novo approach using a 3 dimensional (3D) protein homology modelling 
server (CHPmodels 3.2), in addition to four protein-secondary-structure prediction servers (Porter+, 
PSIPRED, GOR4 and Prof). These computational methods have been shown to be able to predict 
protein secondary structure at high accuracy.15-19 Consistent with previous work9, the predicted 
conformation of the p1 epitope within Na-APR-1 was mostly α-helical, with only a small fragment on 
the N-terminus forming a β sheet. Therefore, it was originally assumed that in order to generate 
peptide-induced conformational antibodies against Na-APR-1, the peptide epitope needed to possess 
high α-helical content within its structure. For this reason, the GCN4 peptide, previously shown to 
induce α-helicity in short peptides once incorporated as flanking sequence25, was introduced into the 
peptide design. Additionally, we expected that elongation of the p1 peptide (using parent protein 
sequence) would also be able to stabilize α-helical conformation of the epitope. Accordingly, 
iterations of different combinations of peptide sequences were analysed. Both GCN4 flanked (p2) and 
elongated peptides (p3) were projected to form α-helices. Computational analysis did not show the 
propensity of β sheet formation at the N-termini for both peptides. Therefore, peptide sequences with 
the highest tendency to form helices were chosen for further investigation (Figure 2). 
Peptide epitopes (p1-p3) and their LCP counterparts (1-3) were synthesized via stepwise SPPS in 
similar manner as previously reported.13,26,27 In addition, the p2 peptide was conjugated to LCP cores 
via CuAAC to generate LCP compounds 4 and 5 (the compound library is illustrated in Figure 1). 
The CuAAC approach (SUPPLEMENTARY MATERIALS Figure S1) was utilized, as a conjugation 
of purified, smaller (in molecular weight) peptide building blocks, allowed us to easily produce pure 
final products, in high yield.24,28,29 The CuAAC reaction progress was monitored via HPLC and ESI-
MS and the final CuAAC products were purified using HPLC, to remove excess of peptides and 
copper. During the CuAAC conjugation, instead of using the classical copper (I) or copper (II)-
reducing agent system, copper wire (Cu0) was applied as catalyst for the CuAAC reaction. There are 
!several advantages of using Cu0 as the copper source: (1) the presence of a copper (I) repository, (2) 
the abolition of reducing and stabilizing agents during reaction, (3) easy removal of excess copper 
upon reaction completion and (4) the possibility of reusing the copper wire for subsequent reactions 
(cost effectiveness).29,30 The practice of using copper for production of compounds for biological 
application might be debatable due to its toxicity.31 Thus, the copper content in both constructs (LCP 
4 and 5) was analysed upon HPLC purification. ICP-OES analyses showed negligible amounts (less 
than 0.1 ppm) of copper in each sample. The allowable safe limit for copper traces in water is 
recommended to be below 15 ppm31, making our approach of using Cu0 for CuAAC reactions safely 
applicable for the production of other pharmaceuticals. 
We demonstrated that all LCP constructs were able to self-assemble to form nanoparticles (<100 nm), 
as confirmed by DLS analysis (Table 1) and TEM images (Figure 3). This size range was reported to 
be preferable to induce humoral immunity.29,32,33 LCPs synthesized via stepwise SPPS (LCP 1, 2 and 
3) showed the formation of bigger particles as compared to LCPs synthesized via the CuAAC 
approach (LCP 4 and 5), even though LCP 2, 4 and 5 possess the same epitope (p2). This observation 
might be explained by the fact that LCP 4 and 5 possess p2 attached through its N-terminus with the 
more polar C-terminal fragment (from the GCN4 peptide) exposed to the aqueous environment 
whereas the same epitope (p2) found in LCP 2 is conjugated to the lipophilic LCP core via the 
hydrophilic C-terminus. 
The antigenicity of the vaccine candidates were assessed in mice by immunization with either LCPs 
(1-5) or peptides (p1-p3) emulsified with Freund’s adjuvants. Production of IgG antibodies were 
measured on p1- and p3-coated ELISA plates (Figure 5) as these two peptides have a peptide 
sequence identical to the parent protein (Na-APR-1). Indeed, all samples were able to induce 
statistically significant production of p1-specific antibodies compared to PBS, illustrating that the 
peptides and LCP compounds were able to induce antibodies which recognize the original B-cell 
epitope sequence (A291Y). No correlation between particle sizes of LCP constructs and their 
immunogenicity was observed. Only CFA + p3 and 3 immunogens were able to induce the 
production of high level p3-specific IgG antibodies. Epitope p1 + CFA induced weaker p3-specific 
!IgG titres despite the p3 peptide sequence including the p1 peptide sequence. Moreover, the 
incorporation of the GCN4 flanking peptide into LCP 2, 4 and 5 was not effective in enhancing the 
production of antibodies against p1 or p3. This observation suggested that the peptides (p1-p3) 
adopted different conformations (even though they were designed to possess similar conformational 
properties). To verify this hypothesis, CD analysis was performed (Figure 4). Computational 
prediction and CD analyses of the peptides correlated well for all peptides and most LCP compounds 
(showing α-helical content) except for LCP 3 where formation of a β sheet was observed. The 
observation that this conformation induced the production of high p3-specific IgG titres may suggest 
the presence of a minimal B-cell epitope within the N-terminal fragment of p1 and p3 as this fragment 
within Na-APR-1 was expected to form a β sheet while in the p1 peptide alone, it was predicted to 
adopt a random conformation. As such, our initial assumption that the dominant antigenic determinant 
was the major α-helical component of the epitope was inaccurate. Rather, the short β sheet (and 
possibly the small fragment of the α-helix adjacent to it makes up the dominant conformational 
antigenic structure (minimal B-cell epitope) as we observed that antibodies produced against LCP 1 
were also able to bind (weakly) to the p3-coated plate. Further, antibodies against LCPs with strong α-
helical content (LCP 2, 4 and 5) were not able to efficiently recognize the p3 peptide. Most definitive 
was the observation that only antibodies produced against the p3 epitope were able to recognize the 
parent protein (Figure 6), suggesting that β sheet conformation of the peptide epitope is crucial for 
production of neutralizing antibodies against Na-APR-1.  
In conclusion, we have designed, synthesized and evaluated conformational peptide epitopes 
based on a neutralising epitope (A291Y) from the hookworm aspartic protease Na-APR-1 with a view 
to developing peptide-based vaccine candidates against hookworm parasites. It was found that  
peptide epitopes incorporated into the LCP system were able to induce humoral responses without the 
presence of potentially toxic adjuvants but only an elongated A291Y peptide with a β sheet 
conformation was able to elicit high IgG antibody titers specific to Na-APR-1. Not only has this work 
provided insight into the importance of epitope conformation for the design of peptidic 
!immunotherapies, it is an important step forward in the development of an epitope-based vaccine for 
human hookworm disease.  
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!FIGURES!
!
Figure 1: Structure of lipid core peptides (LCPs). A. LCPs were synthesized via standard SPPS; B. 
LCPs were synthesized through conjugation of the N-terminus of p2 to an LCP core via CuAAC. 
Single-letter amino acid code; A, alanine; C, cysteine; D, aspartic acid; E, glutamic acid; F, phenyl 
!alanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, 
proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine. 
 
 
Figure 2: Selected peptides for vaccine construction and their corresponding predictions using the 
secondary structure prediction servers. (‘α’ represents helix; ‘β’ represents beta sheet; ‘-’ represents 
random coil). Amino acid conformation based on CHPmodels 3.2 server was manually analysed 
based on the protein conformation presented in the 3D model.  
!
 
! 
Figure 3: Transmission electron microscopy (TEM) structures of LCP compounds upon self-
assembly in PBS. The presence of the LCP system resulted in the formation of nanoparticles of 
varying sizes. 
 
 
Figure 4: Normalized circular dichroism (CD) spectra of peptides and LCP comopounds in PBS;  
A. Peptide epitopes p1-p3. B. LCP compounds 1-5. 
!
 
! 
Figure 5: (A) p1- and (B) p3-specific antibody titres measured 73 days post-primary immunization 
with peptides (p1-p3) and LCP compounds (1-5). Mean specific antibody titres are represented as a 
bar. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by 
Tukey’s multiple comparison test. PBS: Phosphate-buffered saline; CFA: Complete Freund’s 
adjuvant. * p < 0.05; *** p < 0.001; ns: Not significant (p > 0.05). 
 
 
Figure 6: Pooled purified anti-peptide and -compound IgG responses to Na-APR-1. OD415 readings 
are blank corrected OD415 at 1 µg quantity. PBS: Phosphate-buffered saline; CFA: Complete Freund’s 
adjuvant; mAb: monoclonal antibody.* p < 0.05; *** p < 0.001; **** p < 0.0001; ns: Not significant 
(p > 0.05). 
!TABLE!
Table 1: Size analysis of constructs using DLS (size by number) and TEM (extracted values). 
LCP Compounds DLS (nm) TEM (nm) 
1 24 ± 06 25 - 55 
2 43 ± 06 20 - 55 
3 28 ± 09 15 - 35 
4 12 ± 10 10 - 20 
5 18 ± 16 5 - 15 
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Chapter Five 
Lipopeptide Vaccines against Schistosoma 
mansoni (schistosome) 
 
 
 
 
 
 
 
 
 
 
 
 
“The use of conformational cathepsin D-derived epitope for vaccine 
development against Schistosoma mansoni” 
 
 
Ahmad Fuaad, A. A. H., Pearson, M. S., Becker, L., Zhao, G., Loukas, A. C., 
Skwarczynski, M., Toth, I., Development of Lipopeptide Vaccines against Schistosoma 
mansoni. Bioorganic and Medicinal Chemistry. (Submitted) 
 
 
5.1 Introduction to this publication 
This chapter was submitted to Bioorganic and Medicinal Chemistry as an original article. In 
this manuscript, the development of vaccine candidates composed of three components (B 
cell epitope, T cell epitope, lipid carrier), the synthesis protocols and the production of 
antibodies in animal were investigated. The lead vaccine candidate was able to produce 
high level of IgG antibodies, comparable to the positive control (peptide formulated with 
complete Freund’s adjuvant). 
 
 
5.2 Reprint of article in Bioorganic & Medicinal Chemistry submission format 
 
Title: The use of a conformational cathepsin D-derived epitope for vaccine development 
against Schistosoma mansoni. 
 
Graphical Abstract 
 
Abstract: 
Schistosomiasis is caused by the infection from Schistosoma species. Among these, S. 
mansoni is one of the major species that infects millions of people worldwide. The use of 
praziquantel is effective in clearing the infestation but treatment of a large and widespread 
population in endemic areas is unsustainable. Thus, synergistic approach of using drug and 
vaccination can serve as an alternative to the current treatment. In this study, we have 
developed vaccine candidates that composed of three components: a B-cell epitope derived 
from S. mansoni cathepsin D protein (Sm-CatD) flanked by GCN4 helix promoting peptide; a 
promiscuous T-helper epitope (P25); and a lipid core peptide system, in attempt to develop 
self-adjuvanting vaccine candidates against the schistosome. Physicochemical properties of 
the vaccine candidates were analysed and antibodies to each construct were raised in 
BALB/c mice. The vaccine candidates were able to self-assemble into particles that induced 
high titres of IgG without the use of additional adjuvant. The antibody levels were 
comparable to that induced by peptide formulated with strong but toxic Freund’s adjuvant. 
The integration of a GCN4 sequence induced the helical conformation of the epitope, while 
the addition of the T helper peptide was very effective in inducing consistent IgG-specific 
antibodies response amongst mice. These findings are particularly encouraging for the 
development of efficient and immunogenic vaccine against schistosomiasis. 
 
 
Keywords: Nanoparticles; subunit peptide-based vaccine; lipid core peptide; epitope 
modification; peptide conformation; self-assembly; schistosomiasis; Schistosoma mansoni. 
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1. Introduction 
Schistosomiasis is caused by infection with human helminth parasites of the genus 
Schistosoma and is one of the 17 neglected tropical diseases identified by the World Health 
Organization (WHO).1,2 The disease affects over 200 million people in more than 70 
developing tropical countries and a further 750 million people are at risk of infection. Patients 
with schistosome infection, especially children, suffer from many health problems such as 
iron deficiency anaemia and malnutrition, which can retard mental and physical 
development.1,3 Praziquantel is the only available chemotherapy used to treat the infection 
and, while the drug is generally safe and effective, treatment does not prevent reinfection 
(which can occur rapidly in endemic areas).4,5 Furthermore, the continual use of mass drug 
administration (MDA) to treat such a large and widespread population is unsustainable and 
attempts at eradicating the disease in only a handful of countries through the use of MDA 
programmes has been unsuccessful.6 Additional treatment measures are sorely needed and 
a synergistic approach, such as combining the use of chemotherapy and vaccination, would 
be a major advantage in reducing the morbidity caused by schistosome infection. 
Schistosomes and other parasites are obligate blood-feeders, using host haemoglobin as 
their primary food source. As such, there has been a long-standing interest in the 
development of protein subunit-based vaccines that target the gut digestive proteases of 
these organisms. Such vaccines have proven efficacious in in vitro assays and animal 
models and are likely exerting their effects by producing antibodies that neutralize parasite-
derived derived digestive enzymes, impairing the parasites’ ability to acquire nutrients.7 
The major digestive enzyme of S. mansoni is a cathepsin D aspartic protease (Sm-CatD). 
RNAi-induced silencing of Sm-CatD results in a lethal developmental phenotype when 
parasites are injected into mice after treatment with double-stranded RNA in vitro8 and a 
homologue of this protein from a related schistosome parasite, Schistosoma japonicum, was 
shown to be an effective vaccine, affording protection to mice upon vaccination with a 
recombinant enzyme and subsequent challenge with parasites, attesting to the importance 
of this enzyme in parasite survival.9 
In a first for schistosomiasis research, we previously reported the development of a self-
adjuvanting lipid core peptide (LCP) vaccine against S. mansoni using the neutralising A263K 
epitope derived from Sm-CatD.10 Antibodies generated by our LCP construct were able to 
bind and neutralize enzymatic activity of Sm-CatD present in schistosome protein extracts. 
However, antibody production was inconsistent between mice from two separate 
experiments.10 To overcome this inconsistency, we have developed a multi epitope LCP 
system which incorporates the A263K epitope flanked by newly designed α-helicity promoting 
sequence from the yeast GCN4 protein as well as a promiscuous T helper epitope (P25, 
KLIPNASLIENCTKAEL) derived from canine distemper virus. The integration of a GCN4 
sequence should maximise the likelihood of the peptide adopting a conformation similar to 
the native protein10, 11 while incorporation of the T helper epitope in vaccines is highly 
desirable for the induction of humoral immune responses.12, 13 
 
2. Results 
2.1 B-cell epitope design 
The Sm-CatD protein epitope, A263K (AGPTDEIQKINAK), was chosen for vaccine 
development because of its ability to induce neutralising antibodies upon vaccination.10 
Based on homology modelling using human cathepsin E, we have designed a new 
conformational derivative of this epitope (p2) using a bioinformatics approach. To ensure the 
epitope is able to form the desired helical conformation, the GCN4 helix-promoting sequence 
was incorporated as a flanking moiety at the C- and N-termini of A263K. As a comparison, p1 
(a previously reported analogue of A263K peptide epitope) 10 conformations was also 
analysed using the same approach (Fig. 1). It was predicted that both p1 and p2 have 
similar tendencies to form helices, however, p1 was predicted to form helices at both N- and 
C- termini regions of the A263K epitope while p2 showed only the C-terminus region of the 
A263K epitope was predisposed to form helices. 
 
2.2 Synthesis and particle size analyses 
Peptides and LCPs (Fig. 2) were readily synthesized on p-methylbenzhydrylamine resin 
(pMBHA) via t-butyloxycarbonyl (Boc) chemistry using microwave-assisted solid-phase 
peptide synthesis. For the LCPs synthesis, Boc-Lys(Fmoc)-OH amino acid was used as the 
branching moiety in the LCP system as it contains the orthogonal Boc protecting group, 
fluorenylmethyloxycarbonyl (Fmoc). Following T-helper epitope synthesis, the N-terminus 
was acetylated then; the Fmoc group was deprotected to allow the synthesis of the second 
epitope. Finally, the N-terminus was acetylated to give the final LCP constructs. All of the 
compounds were subjected to RP-HPLC purification with purity of greater than 95% used for 
the subsequent experiments.  
Particle size has an impact in the magnitude of the immune response. As such, the particle 
formations of the compounds were investigated. When dissolved in PBS, the amphiphilic 
properties of the lipopeptides (LCP 1 and LCP 2) promoted the self-assembly of the 
constructs into particles. Size analysis of the LCPs via DLS and TEM (Fig. 3) illustrated the 
formation of nano-sized particulates (Table 1). As expected, the short peptides (p1 and p2) 
were not able to form particles when observed under TEM (DLS results showed high 
polydispersity). 
 
2.3 Secondary structure studies 
Basic principle of antibody production via peptide-based vaccination is the peptide (B-cell 
epitope) secondary structure must adopt similar conformation to its native protein target. As 
such, the conformations of the vaccine candidates were analysed using circular dichroism 
(CD) spectroscopy. CD spectra of peptides and LCPs are displayed in Fig. 4. Spectrum for 
peptides p1 and p2 suggested the formation of a secondary structure that was more random 
than α-helical. Spectra for p1 showed a deep minimum at 202 nm and a shallow minimum at 
221 nm, while spectra for p2 illustrated strong and weak minima at 203 nm 220 nm, 
respectively. Spectra for both LCPs suggested formation of α-helical secondary structures 
with minima at 207/220 nm for LCP 1, and 208/220 nm for LCP 2. 
 
2.4 IgG antibody titres 
A263K-specific IgG antibody titres were determined using p1- and p2-coated ELISA plates 
(Fig. 5). The levels of p1-specific antibodies generated by Freund’s adjuvanted peptides and 
LCP 1 were significantly higher than the negative control (Fig. 5A). However, mice 
administered with LCP 2 were not able to induce p1-specific IgG antibodies. Additionally, 
mice administered with Freund’s-adjuvanted p2 were able to produce significantly higher 
antibodies against p1 antigen than mice administered with LCP 2. There was no significant 
difference between antibody levels from mice administered with Freund’s-adjuvanted p1 and 
LCP 1. 
All compounds were able to induce significant p2-specific IgG antibodies compared to PBS 
(Fig. 5B). Antibodies against LCP 1 and Freund’s-adjuvanted p1 showed significantly 
weaker p2-specific titres than antibodies against p2 antigens.  LCP constructs were able to 
induce similar titres to their Freund’s adjuvanted counterparts. 
3. Discussion 
Schistosomiasis is a chronic and debilitating disease, which, despite concentrated control 
efforts using chemotherapeutics, is still highly prevalent in the developing tropics.2 
Vaccination against schistosomiasis, therefore, in combination with drug treatment, is 
considered as the most effective strategy to combat this disease. 
Previously, we investigated the vaccine potential (using antibody inhibition assays) of LCPs 
based on the neutralising A263K epitope from Sm-CatD.10 Vaccine candidates were 
constructed using self-adjuvanting LCP technology14 and consisted of either the parent A263K 
epitope or the A263K epitope flanked with the GCN4 helix-promoting sequence (p1 in this 
study) linked to the LCP. It was found that the integration of the GCN4 helical component 
was essential for the generation of a neutralizing immune response against the Sm-CatD 
protein. However, inconsistencies in antibody production from two different mice 
experiments were clearly observed.10 To overcome this drawback, we herein developed self-
adjuvanting LCP vaccine candidates incorporating a promiscuous T-helper epitope with the 
previously developed p1 peptide (LCP 1) and the newly designed p2 peptide (LCP 2). We 
hypothesized that the inconsistencies in antibody production could be overcome with the 
addition of a T-helper epitope as this motif is essential to promote proliferation of T-helper 
cells which provide the stimulus for B-cell maturation.15 Additionally, we reasoned that further 
modification of the flanking CGN4 sequence should be able to enhance natural helical 
formation within A263K, resulting in antibodies that are better at recognizing this epitope 
within Sm-CatD. 
The P25 T-helper epitope that was incorporated into the LCP vaccine design was derived 
from canine distemper virus and has been reported to be a strong proliferator of peripheral 
blood mononuclear cells (PBMC), the group of cells that play critical role in the immune 
system.12 Further, we have previously shown that the incorporation of this epitope in an anti-
streptococcal LCP-based vaccine resulted in consistent production of IgG upon 
administration of the antigen to a heterogeneous, outbred population of mice.13 Structure-
activity relationship studies by us showed that conjugation of the T-helper epitope at the α-
amine position of the lysine branching unit resulted in better humoral responses than if it was 
positioned at the ε-amine position16-18, therefore, the P25 epitope was conjugated at this 
position in LCP1 and LCP2. 
The GCN4 sequence was incorporated as a flanking unit to the A263K peptide to maximise 
the likelihood that the B-cell epitope possessed a matching secondary structure to the 
conformation within Sm-CatD. Accordingly, bioinformatics tools (Porter, PSIPRED, GOR4 
and Prof) were utilized to predict a new GCN4 epitope with enhanced α-helical promoting 
properties. These prediction tools were chosen as they were previously reported to be able 
to predict protein secondary structure at high accuracy.19-22 Ultimately, we constructed two 
peptide antigens and two vaccine candidates via microwave-assisted Boc-SPPS: the 
previously designed construct consisting of the parent A263K peptide and flanking GCN-4 
moieties (p1), a new construct comprising the parent A263K peptide with newly designed 
flanking GCN4 sequences (p2) and LCP-conjugates of each of these with the addition of a 
P25 T-helper epitope (LCP 1 and LCP 2, respectively). 
In many instances, LCP-based vaccine candidates have been able to self-assemble into 
particles in an aqueous environment.23-25 Herein, both LCP vaccine candidates were able to 
form particles (40 nm to 150 nm) in PBS as confirmed by TEM and DLS analyses. In 
contrast, previous reports showed narrower particle size distribution when only identical 
epitopes were attached to the LCP core26,27; thus, the incorporation of the second epitope 
(i.e. P25), might have disrupted the self-assembly of the LCP constructs. Nevertheless, 
particles in the size range we observed are commonly reported to induce efficient humoral 
immunity28-32; as such, we expected that the vaccine candidates should be able to induce 
high antibody titers. 
CD spectroscopy was used to confirm predicted secondary structure of the epitopes. 
Spectra for the non-adjuvanted peptides displayed weak α-helical formation despite 
incorporation of the GCN4 helix promoting sequence. However, once the peptides were 
conjugated to an LCP core, a more typical α-helical conformation was adopted due to the 
organized packing of the peptides within the micellized structure.26,33  
To evaluate the antigenicity of the LCP constructs, p1- and p2-specific serum IgG antibody 
titres were measured following immunization in BALB/c mice. Even without the use of 
additional adjuvant, LCP 1 and LCP 2 were able to induce significant antibody responses 
compared to the control PBS group. The fact that both LCPs generated similar IgG titres 
suggests that the P25 epitope generated effective T cell help with the induction of a B-cell 
response. Similar observations were previously reported when P25 was used in vaccine 
development against group A streptococcus17,18, highlighting the advantages of integrating a 
universal T-helper epitope into a synthetic vaccine.  
All mice were able to generate significant peptide-specific antibody responses but those 
immunized with LCP 2 could not mount a p1-specific antibody response despite the 
presence of the A263K epitope within the construct. The ability of LCP 1 (in contrast to LCP 
2) to generate both p1- and p2-specific antibodies suggested that this construct is able to 
induce antibody production against A263K which is present in both p1 and p2 immunogens. 
Interestingly, when the same p1 and p2 were administered with Freund’s adjuvant, such 
epitope specificity was not observed.  This observation suggests that the incorporation of a 
longer GCN4 sequence at the N-terminus of the p1 peptide in LCP 1 might be fundamental 
for antigen processing by providing an additional scaffold to assist immune cells in 
processing the A263K region of p134, or the GCN4 sequence at the C-terminus of p2 in LCP 2 
resulted in a more dominant antigenic determinant against itself than A263K.35 Thus, while it 
is relatively easy to predict an epitope conformation, it is not always possible to envisage its 
immunological properties in silico as any epitope modification may have unexpected 
influences on the immunogenicity of an antigen. 
Interestingly, the larger sized LCP 2 (in contrast to LCP 1), more efficiently induced peptide-
specific antibody production contrary to most reports where smaller nanoparticles were more 
efficient in induction of immune responses.29,31 However, as epitope p2 may include a more 
dominant antigenic determinant, this difference might be not related to the size of particle 
formed by the LCPs. As such, the difference in particles size was less influential in the 
induction of antibody response compared to the epitopes conformations. 
 
4. Conclusions 
Recently, we have reported the first peptide-based vaccine against the human blood fluke 
Schistosoma mansoni, which targeted cathepsin D, a major digestive protease secreted by 
the parasite.  To improve the immunogenicity of this vaccine, we incorporated a promiscuous 
P25 T-helper epitope and a novel, GCN4-flanked, A263K (B-cell) epitope into our self-
adjuvanting lipid core peptide (LCP) system. The LCPs were able to self-assemble into 
particles in PBS and induce consistently high levels of p1- and p2-specific IgG antibodies 
without the use of additional immune-stimulants, producing titers comparable to those 
induced by peptide formulated with strong but toxic Freund’s adjuvant. The integration of 
GCN4 sequence is a promising strategy to induce helical conformation of the epitope. 
However, immune response against GCN4 peptides can be expected. Thus, the GCN4-
flanked epitopes need to be carefully examined toward their ability to induce immune 
responses against desired peptide fragment.  Finally, addition of P25 T helper was very 
effective in inducing consistent A263K specific antibodies response. These findings are 
particularly encouraging for the development of efficient and immunogenic vaccine against 
schistosomiasis. 
 
5. Materials and methods 
5.1 Materials 
pMBHA Resin (0.57 mmol/g, 100-200 mesh) was purchased from Peptides International Inc. 
(Kentucky, USA). HPLC grade acetonitrile and N,N-dimethylformamide (DMF) were 
purchased from Ajax Finechem (Victoria, Australia) N,N-diisopropylethylamine (DIPEA), 
trifluoroacetic acid (TFA), diethyl ether, dichloromethane (DCM) and piperidine were 
obtained from Merck (Darmstadt, Germany). Boc-protected L-amino acids and 2-(1H-7-
azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) were 
obtained from Mimotopes (Melbourne, Australia). Goat anti-mouse immunoglobulin G-horse 
radish peroxidase (IgG-HRP) conjugate was acquired from Millipore (California, USA). 2-
Azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) was obtained from Invitrogen 
(Maryland, USA). Analytical grade Tween 20 was acquired from VWR International 
(Queensland, Australia). All other reagents were purchased from Sigma-Aldrich (Victoria, 
Australia). Milli-Q™ water equipment (with endotoxin filter, 18.2 MΩm) was obtained from 
New England Biolabs (Queensland, Australia). Microwave-assisted solid phase peptide 
synthesis (SPPS) was carried out using the dynamic mode on a CEM Discovery reactor 
(CME Corporation, North Carolina, USA). An AKel-F HF apparatus (Peptide Institute, Osaka, 
Japan) was used for cleavage of LCPs from the resin. Two solvents, A (0.1% TFA/H2O) and 
B (90% MeCN/0.1% TFA/H2O), were used for purification and analysis on HPLC. 
Preparative RP-HPLC were performed on a Prominence preparative HPLC (Shimadzu 
Scientific Instruments, Australia) over a 0-60% linear gradient of solvent B for 60 minutes 
with a 10 mL/min flow rate and detection at 214 nm. Analytical RP-HPLC was performed 
using Agilent RP-HPLC instruments (Agilent Technologies, Australia) at 1 mL/min flow rate 
for 40 minutes over a 0-100% linear gradient of solvent B in 40 minutes. Separation was 
achieved on a Vydac C4 (for LCPs) or C18 (for peptides) analytical and preparative columns 
(California, USA). Electron spray ionization mass spectrometry (ESI-MS) was performed on 
a Perkin-Elmer-Sciex API3000 using Analyst 1.4 software (Toronto, Canada). Samples (1-10 
µL) were injected into acetonitrile-water mobile phase containing 0.1% (v/v) acetic acid and 
run in positive ion mode. Size analyses were performed using JEM-1010 transmission 
electron microscope (JOEL Ltd. Japan) and Zetasizer Nano ZP instrument (Malvern 
Instrument, United Kingdom). The circular dichroism (CD) spectra were measured using 
Jasco J-710 CD spectropolarimeter (Jasco Corporation, Japan).  
 
 
5.2 Epitope design 
The Sm-CatD was 3D-modelled using human cathepsin E as template as previously 
reported.10 The extracted secondary structure corresponding to the A263K epitope showed 
mostly α-helical conformation at the C-terminus and, based on this information, we designed 
a new A263K peptide by flanking the epitope sequence with the GCN4 peptide to promote α-
helical formation. After the design was optimized using bioinformatics tools (Porter 22 
http://distill.ucd.ie/porter/, PSIPRED 20 http://bioinf.cs.ucl.ac.uk/psipred/, GOR4 19 http://npsa-
pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_gor4.html and Prof 21 
http://www.aber.ac.uk/~phiwww/prof/), the new chimeric epitope p2 (A263K flanked with 
GCN4 - EDKVAGPTDEIQKINAKKQAEDKVKQLE) was selected as it possessed high 
helical content within its secondary structure (Fig. 1). 
 
5.3 LCP and peptide syntheses and characterizations 
Peptides and LCP constructs (Fig. 2) were synthesized using microwave-assisted solid 
phase peptide synthesis (SPPS) using pMBHA resin at 0.1 mmol scale. The syntheses were 
performed in similar manner as previously reported.14, 26, 36 Briefly, amino acids (4.2 equiv.) 
were pre-activated using HATU/DMF 0.5 M solution (4.0 equiv.) and DIPEA (6.2 equiv.) for 1 
- 2 minutes prior to coupling, except for lipoamino acids pre-activation which was left for 5 
minutes. Microwave-assisted SPPS was then performed for amino acid couplings and Fmoc-
deprotection (LCP branching unit). Each amino acid was double coupled (5 minutes at 70 
°C) to ensure maximum coupling efficiency. Boc-deprotection was executed using TFA (2 x 
1 minute) followed by a DMF flow wash (3 x 10 mL) between each amino acid. Boc-
Lys(Fmoc)-OH was used for the epitope branching during LCP synthesis. Fmoc-deprotection 
(20% piperidine/DMF) was performed prior to the synthesis of the second epitope. Products 
were cleaved by HF apparatus27 using a HF/thiocresol/cresol (90/5/5% v/v) cocktail mixture 
at -5 °C. 
5.3.1 Peptide 1 (p1) 
Yield: 67%. Molecular Weight: 3193.7. ESI-MS [M + 2H+]2+ m/z 1598.2 (calc. 1597.8). [M + 
3H+]3+ m/z 1065.9 (calc. 1065.5), [M + 4H+]4+ m/z 799.4 (calc. 799.4),  
[M + 5H+]5+ m/z 640.0 (calc. 639.7), [M + 6H+]6+ m/z 533.4 (calc. 533.3), [M + 7H+]7+ m/z 
457.4 (calc. 457.2). tR = 16.2 min (0 – 100% Solvent B; C18 column), purity ≥ 95%. 
 
 
5.3.2 Peptide 2 (p2) 
Yield: 61%. Molecular Weight: 3196.6. ESI-MS [M + 2H+]2+ m/z 1598.1 (calc. 1598.3). [M + 
3H+]3+ m/z 1066.1 (calc. 1065.9), [M + 4H+]4+ m/z 799.7 (calc. 799.6), [M + 5H+]5+ m/z 640.0 
(calc. 639.9), [M + 6H+]6+ m/z 533.6 (calc. 533.4). tR = 16.4 min (0 – 100% Solvent B; C18 
column), purity ≥ 95%. 
5.3.3 LCP 1 
Yield: 35%. Molecular Weight: 5884.07. ESI-MS [M + 4H+]4+ m/z 1472.4 (calc. 1472.0), [M + 
5H+]5+ m/z 1177.6 (calc. 1177.8), [M + 6H+]6+ m/z 981.9 (calc. 981.7),  
[M + 7H+]7+ m/z 841.8 (calc. 841.6), [M + 8H+]8+ m/z 736.7 (calc. 736.5). tR = 27.1 min (0 – 
100% Solvent B; C4 column), purity ≥ 95%. 
5.3.4 LCP 2 
Yield: 28%. Molecular Weight: 5885.01. ESI-MS [M + 3H+]3+ m/z 1963.5 (calc.1962.7) [M + 
4H+]4+ m/z 1472.2 (calc. 1472.2), [M + 5H+]5+ m/z 1178.1 (calc. 1178.0), [M + 6H+]6+ m/z 
982.2 (calc. 981.8), [M + 7H+]7+ m/z 841.9 (calc. 841.7). tR = 27.6 min (0 – 100% Solvent B; 
C4 column), purity ≥ 95%. 
 
5.4 Particle size analysis 
For transmission electron microscopy (TEM) analysis, LCPs were dissolved in phosphate 
buffer saline (PBS), at 1 mg/mL and a sample (10 µL) was put onto a 200-square mesh, 
ionized, carbon coated copper grid, for one minute. The solution was dried using filter paper 
and the application and drying process repeated. The copper grid was inserted into the 
electron microscope, which was operated at 100 kV, for analysis. For analysis by dynamic 
light scattering (DLS), 800 µL of LCP (1 mg/mL in PBS) was transferred into a disposable 
low volume plastic cuvette, and measured with a Zetasizer Nano ZP instrument. Particle size 
measurements were performed using the M3-PALS technique with a 173° backscattering 
angle, at 25 °C. Measurement was performed in triplicate. 
 
5.5 Peptide secondary structure studies 
Four hundred microliters of each peptide and LCP (1 mg/mL in PBS) was transferred into a 
low volume quartz cuvette (1.0 mm) and spectral analyses were carried out between 260 nm 
and 190 nm wavelengths. Spectral data (an average of triplicate readings) was presented as 
mean residual ellipticity (θ) versus wavelength (nm). 
5.6 Immunization and serum collection 
All protocols were approved by the James Cook University Animal Ethics Committee (Animal 
ethics number A2004) on 11 February 2014 and experiments were carried out in accordance 
with National Health and Medical Research Council (NHMRC) of Australia guidelines. LCPs 
and peptides were administered intraperitoneally to groups of five female BALB/C mice 
(Animal Resource Centre, Perth, Australia, 4-6 weeks old). Mice received either 30 µg of 
immunogen in 100 µL of PBS or in 100 µL of emulsified Freund’s adjuvant/PBS (50% v/v), at 
day 0, 21, 33, and 45. The negative control group received 100 µL of PBS throughout the 
experiment. Mice were euthanized using carbon dioxide on day 73-post immunization. Blood 
was collected via cardiac puncture and serum was separated using Z-Gel micro tube 
(Sarstedt AG & Co, Nümbrecht, Germany) at 3000 rpm for 10 minutes. Sera were stored at -
80 °C. 
 
5.7 Antibody titre determination via ELISA 
Indirect enzyme-linked immunosorbent assay (ELISA) was used to determine the IgG 
antibody titre. Peptide antigen (p1 or p2; 5 µg/mL in 20 mM sodium carbonate buffer) was 
used to coat polycarbonate 96-well flat bottom ELISA plates overnight at 4 °C. Unbound 
antigens were removed and plates washed in endotoxin-free Milli-Q™ water for a minimum 
of three times. Non-reactive sites within wells were then blocked using 5 % skim milk in 0.05 
% Tween 20/PBS and incubated at 37 °C for 1.5 hours. Plates were washed in a similar 
manner between incubations. Individual sera (1:100 to 1:12800 in blocking buffer) were 
added and plates were incubated at 37 °C for 1.5 hours. Primary IgG binding was detected 
using goat anti-mouse IgG-HRP (1:5000 in blocking buffer) at 37 °C for 1.5 hours. 
Secondary IgG binding was detected with ABTS (Invitrogen, Maryland, USA). Plates were 
read at 415 nm on a POLARstar Omega microplate reader (BMGLabtech, Victoria, Australia) 
and antibody endpoint titres determined by the lowest dilution factor that gave an absorption 
value of >3SD above the mean absorbance of their respective control wells. 
 
5.8 Statistical analysis 
Statistical analysis of antibody titres between groups was performed using a one-way 
analysis of variance (ANOVA) followed by the Tukey’s multiple comparisons test. GraphPad 
Prism® 6.0 software (Graph-Pad Software Inc., USA) was used for the statistical analysis. 
Values were considered significant if p < 0.05.  
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FIGURES 
 
Figure 1: Peptide p1 and p2 prediction using secondary structure prediction software. 
Parent peptide from CatD protein was shown in bold. ‘α’ represent helix, ‘β’ represent beta 
sheet and ‘-‘ represent random coil secondary structures. Single-letter amino acid code; A, 
alanine; C, cysteine; D, aspartic acid; E, glutamic acid; F, phenyl alanine; G, glycine; H, 
histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, 
glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine. * Amino 
acids secondary structures were described by Dougall et. al.[10] 
 
 
Figure 2: General structure of vaccine constructs. The vaccines were composed of three 
components; a lipid moiety (LCP), a T-helper peptide epitope (P25) and a B-cell peptide 
epitope (peptide p1 or p2). 
 Figure 3: Transmission electron microscopy images of self-assembled: (a) LCP 1; (b) LCP 
2; in PBS. 
 
 
Figure 4: Normalized circular dichroism spectra of peptides and LCPs in PBS.  
 
 Figure 5: Enzyme-linked immunosorbent assay; (a) p1-; (b) p2-, specific IgG antibody 
binding. Mean specific antibody titres are represented as a bar. PBS: Phosphate-buffered 
saline; CFA: Complete Freund’s adjuvant. ** p < 0.01; **** p < 0.0001; ns: Not significant (p 
> 0.05). 
 
 
TABLE 
Table 1. Particle size analysis of LCP constructs via DLS (size by intensity) and TEM 
(extracted dimensions). 
Vaccine 
Candidates 
DLS (nm) TEM (nm) 
LCP 1 78 ± 49 30 - 60 
LCP 2 141 ± 91  70 - 130 
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Chapter Six 
Conclusions and Future Prospect 
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Although clinical use of chemotherapy drugs is effective in the remediation of the infections 
caused by GAS, hookworm and schistosomes, many people are still suffering from these 
agonizing infections. Vaccination can be one of the most promising disease control 
strategies – or a complementary strategy to the chemotherapy. Nonetheless, there are no 
vaccines against these diseases on the market. Vaccine candidates developed via the 
traditional approach are hampered with undesirable side effects, i.e. autoimmune disease 
(GAS) and allergic responses (hookworm and schistosome). To overcome these 
problems, the subunit peptide-based vaccine approach was employed using polymer- and 
lipopeptide-based carrier systems. The vaccine constructs presented in this thesis 
exemplifies novel approaches for the development of safe (well-defined) and effective 
vaccines. The synthesis of the peptide-carrier system hybrids via SPPS or CuAAC 
reaction to produce self-adjuvanting vaccines eliminated the dependency of using toxic 
adjuvants in the vaccine formulation. The preliminary data showed that the carrier systems 
were able to stimulate antibody productions against the short peptide epitopes. 
 
The thesis aimed to report the preliminary discoveries of the vaccines developed against 
GAS, hookworm and schistosome. In the first study, linear and dendritic polyacrylate 
polymer platforms were utilized for the development of vaccines against GAS. The 
polymers were easily synthesized, cheap and contain little or no toxicity. Multiple copies of 
J14 peptide (GAS B cell epitope) were conjugated to the polymer carriers via the CuAAC 
reaction. The architecture of the final vaccine constructs bearing lipophilic polymeric core 
and hydrophilic surface peptides enabled the constructs to self-assemble into micelle-like 
particles. The J14-dendritic polymer hybrid formed approximately 20 nm particles while the 
J14-linear polymer hybrid formed near micron-sized particles (roughly 550 nm). Following 
a single-dose subcutaneous immunization, the former was able to induce comparable IgG 
antibodies to the positive control, J14 emulsified with a strong but toxic Freund’s adjuvant, 
while the latter provoked lower IgG antibodies than the positive control group but 
significantly higher antibody titres compared to the control group, PBS. The ability of the 
peptide-polymers hybrids to stimulate the antibody production upon a single dose 
administration has shown promising benefits of developing polymer-conjugated vaccine 
candidates with strong and rapid immune responses. 
 
In the second study, the LCP carrier systems were utilized for the development of subunit 
peptide-based vaccines against hookworm parasite. Computational methods were used to 
design new epitopes that possessed similar/close epitope conformation to the native  
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APR-1 protein-sequence. The designed peptide epitopes were conjugated to the LCPs via 
stepwise SPPS or CuAAC reaction. The products, bearing multiple copies of the target 
epitope (hydrophilic) connected to a single lipid core (lipophilic), enabled the constructs to 
self-assemble into particles (with sizes between 5 – 55 nm). The constructs were able to 
stimulate the production of systemic IgG antibodies after three intraperitoneal 
administrations, without additional adjuvants. Moreover, the lead vaccine candidate was 
shown to be able to elicit IgG antibodies that were able to bind to the parent target, the 
APR-1 protein. The importance of epitope conformation for the design of peptidic 
immunotherapies was thus presented. Further prospects include (i) immunization of Swiss 
mice – to investigate the ability of the lead candidate to elicit antibody response in outbred 
population (ii) challenge studies – to examine the viability and survivability of hookworm 
parasite to infect and reproduce in immunized mice (iii) preclinical studies in human – to 
analyse common side effects associated with hookworm vaccines (e. g. allergic response). 
 
The third study focused on the development of vaccine candidates against schistosome 
parasite. The vaccines were designed to encompass three-components: a lipidic core, a T 
helper epitope (P25) and a B cell epitope (derived from schistosome CatD protein 
sequence – A263K). To enhance B cell epitope conformation, the peptide was flanked with 
GCN4 sequence at both N- and C- termini. The final constructs were able to self-
assembled into particles in aqueous solution. Sera were raised in mice and high level of 
IgG antibodies were observed which were comparable to the positive control containing 
peptide formulated with Freund’s adjuvant. Although the GCN4 sequence was important to 
promote helicity, immune response could also be directed towards the sequence. Thus, 
the ability of the GCN4-flanked epitopes needs to be carefully studied to ensure induction 
of immune responses is directed against the desired peptide fragment. Finally, the addition 
of the P25 T helper was very effective at inducing consistent A263K specific IgG antibodies. 
Future studies can include (i) using a shorter GCN4-flanking sequence for optimum B cell 
epitope presentation (ii) immunization of outbred mice (iii) conformational studies using 3D 
imaging techniques (e.g. NMR, crystallography) to delve into the structure-activity 
relationships of the constructs.  
 
Overall, the PtBA polymer- and lipopeptide-based technologies showed great potentials as 
the next generation carrier systems for the development of future vaccines. The abilities of 
the carriers to stimulate the desired immune response are very relevant in the context of 
subunit peptide-based vaccine, where the capacity of the carrier system to overcome the 
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low immunogenicity of peptide antigens are of utmost importance. This study serves as the 
foundation to future research endeavours that could explore the potential of the carrier 
systems as therapeutic strategies against other diseases.  
 
